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Breast cancer is the second most leading cause of death among women in the 
United States. Several environmental and genetic factors contribute to the pathogenesis 
of the disease. It is classified into different subtypes based on expression of certain 
markers as well as that of set of genes that define the disease progression and 
associated mortality. Identification of various subtypes namely: Luminal-like (Luminal-A, 
Luminal-B), ErbB2 over-expressing, Basal-like and Claudin low types, showed an 
association of survival outcomes with that of the corresponding gene expression 
signatures, thus paving a way for therapeutic intervention. It further emphasizes the 
importance of nature of gene expression changes characteristic of each subtype in 
regulating the disease outcome.  Another important factor that determines disease 
phenotype is the nature of cell of origin.  
As part of my thesis research, I investigated the role of different combination of 
oncogenes/tumor–suppressor and the nature of cell type in contributing towards 
phenotypic and pathological differences in development of breast cancer. hTERT 
immortalized stem/progenitor cell lines K5+/K19- and K5+/K19+ when transformed by 
combination of triple oncogene/tumor-suppressor -mRas/mp53/wtErbB2 or 
mRas/mp53/wtEGFR gave rise to heterogeneous primary tumors as well as 
spontaneous lung metastasis in-vivo upon orthotopic transplantation in mammary glands 
of immunocompromised NSG mice. Important tumor characteristics such as latency and 
incidence of primary and metastatic tumors depend on both the nature of cell type and 
oncogene combination. K5+/K19- over-expressing mRas/mp53/wtEGFR had a 
significantly late tumor onset than all other tested cell lines. Transformed K5+/K19+ cells 
overall possess higher anchorage independent growth and metastasis forming ability 
than K5+/K19- cells. From microarray analysis, we observed that tumors from 
transformed K5+/K19- cells have a higher EMT gene signature, more so for K5+/K19- 
over-expressing mRas/mp53/wtErbB2. Tumors from K5+/K19+ cells over-expressing 
mRas/mp53/wtEGFR express known markers for metastasis in BC, accounting for 
higher metastasis ability from these tumors. We also observed complete in-vitro 
transformation and tumor formation from either cell lines following over-expression of 
mRas/mp53/mPI3K oncogene combination. K5+/K19- or K5+/K19+ cells show distinct 
EMT upon over-expression of mRas/mp53/mPI3K combination and overall K5+/K19- 
cells have a higher susceptibility to undergo EMT upon transformation as compared to 
K5+/K19+ cells.  
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1.1 Heterogeneity in Breast Cancer- “Clonal evolution” versus “Cancer Stem Cell” 
hypothesis 
Tumor heterogeneity refers to variation in the genetic, epigenetic or micro-
environmental context of the cells that constitute the tumor.  It is mainly divided as inter 
or intra tumor heterogeneity, where inter-tumor heterogeneity describes the variation in 
tumors from different patients while an intra-tumor heterogeneity constitutes variation 
within a tumor (Visvader 2011). Tumors of human mammary gland are highly 
heterogeneous in nature. Various studies have shown the existence of different sub-
populations within primary breast tumors (Dexter et al., 1978; Fidler, 1978; Shipitsin et 
al., 2007). These variable sub-populations isolated from same primary tumor, when 
cloned and injected in mice, exhibited different metastatic capacity (Fidler, 1978). These 
results, therefore suggested that primary tumors harbor heterogeneous cell populations 
that have distinct growth and invasion abilities and that allow tumors to progress and 
metastasize (Heppner, 1984; Michor and Polyak 2011).  
Many hypotheses have been given to explain these variations within tumors. Two 
most predominant ones are the- “Clonal Evolution” and “Cancer-Stem cell” hypothesis. 
According to the clonal evolution model, heterogeneity in tumor develops as a result of 
accumulation of new mutations in tumor cells that leads to development of various sub-
clones (Michor and Polyak 2011). Several breast cancer cell lines exhibit heterogeneity 
and sub-clones within these cell lines interact with each other to determine the 
pathogenicity of disease (Dexter et al., 1978; Marusyk et al.). These and findings from 
various mouse models emphasize the presence of different cell populations that work 
together under the influence of genetic and microenvironmental forces to determine the 
progression of disease (Cleary et al.,2014; Koren and Bentires-Alj 2015).  
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Besides evolution of different clonal populations, another mechanism that is 
given to account for the heterogeneity is presence of pool of self-renewing and 
differentiating “Cancer Stem Cells” (CSCs). These CSCs are considered to be the tumor 
initiating cells, which maintain the tumor growth by self-renewal and give rise to non-
tumorigenic differentiated progenies, thus accounting for the generation of heterogeneity 
within tumors. Patient derived primary tumor specimens were subjected to FACS and 
analyzed for presence of cells with CD44, CD24 expression. Tumors cells that were 
CD44high, CD24low were able to seed new tumors and propagate and also possessed the 
ability to produce non-tumorigenic progenies that were CD44low, CD24high (Al-Hajj et al., 
2003). When differentiated CD44low, CD24high cells were transplanted in mice no tumor 
formation was observed from them. Therefore suggesting that the tumor stem cell 
behavior was specific to cells with CD44high, CD24low phenotype and these cells have 
been since considered as the CSCs population within tumors. More recently, 
identification of stem cell markers have allowed isolation of normal stem and cancer 
stem cell populations and high throughput sequencing analysis of the isolated breast 
CSCs has provided information about breast cancer heterogeneity (Shipitsin et al., 
2007). Furthermore evidence from different transgenic mice model have also shown 
presence of tumor initiating stem cells within mice tumors (Cho et al., 2008; Zhang et al., 
2008). Many breast cancer cell lines have also shown to have CSCs populations 
(Charafe-Jauffret et al., 2009; Ginestier and Wicha, 2007).   
 
1.2 BC subtypes 
Different methods are used to classify BC it into different types. More classical 
method of tumors classification is based on the expression of growth factor receptors 
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such as ER, PR and ErbB2. Breast tumors are categorized as 1) ER, PR positive 2) 
ErbB2 positive 3) ER, PR, ErbB2 negative and the course of therapy is determined by 
this classification.  In order to better understand the phenotypic variations existent in 
patient tumors, when gene expression analysis of patient derived tumors was done, the 
gene expression patterns associated with each tumor led to clustering of different tumors 
in to a particular subtype (Perou et al., 2000; Sorlie et al., 2001). Profiling of breast 
tumors at molecular level further stratified tumors into various subtypes. These subtypes 
namely: Luminal like (Luminal-A, Luminal-B), ErbB2 over-expressing, Claudin-low type, 
normal-like and basal like are each characterized by the expression of certain genetic 
alterations that are seen among the patients belonging to these subtypes (Prat et 
al.,2010; Sorlie et al., 2001).  Two important findings observed from this study were that 
- 1) different subtypes had characteristic gene expression changes associated with them 
and 2) each subtype had gene signatures that closely resembled those of known cell 
types present in the normal mammary gland i.e. the basal or luminal cells (Perou et al., 
2000). Further analysis of gene alterations in relation to clinical outcomes revealed that 
different subtypes have characteristic survival outcome associated with it, where basal 
subtype had a worse clinical outcome whereas tumor with luminal specific gene 
expression had a good overall survival (Sorlie et al., 2001). Given these findings, we 
therefore sought to study the contributions of both the cell type and/or the oncogene in 
determining BC pathogenesis. 
 
1.3 Models to study BC pathogenesis 
Human mammary gland is organized in to ducts and lobules. Each ductal 
compartment is a bi-layered structure that consists of an inner layer of luminal epithelial 
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cells supported underneath by a basal layer of myoepithelial cells. Interspersed in the 
basal or the sub-basal compartments are the likely stem/progenitors that respond to the 
chemical stimulus i.e. hormones and differentiate to give rise to luminal and 
myoepithelial cells. Mammary gland undergoes periodic remodeling to response to 
different hormones. Upon pregnancy the luminal layer proliferates and differentiates by 
stimulation from estrogen, prolactin, progesterone to become milk secreting cells and the 
basal myoepithelial cells under the influence of oxytocin constrict to facilitate passage of 
milk through the ducts (Wiseman and Werb, 2002). 
Breast cancer originates as a result of transforming event occurring in any of 
these epithelial cell components. Different methods, including isolation of cells from the 
normal reduction mammoplasty or the primary tumor specimens or generation of tumor 
specific mice models have been employed to understand the etiology of the disease. 
Isolation of normal or tumor mammary epithelial cells have been difficult to establish in 
2D culture owing to different growth requirements of different lineages. Various growth 
medium with defined growth factors have since been developed to allow growth of 
hMECS, as well as breast cancer cells in order to isolate these cells and culture them in-
vitro to study disease pathogenesis from them (Band, 2003; Band and Sager, 1989). 
However normal epithelial cells have a limited proliferative capacity and undergo 
replicative senescence after few weeks in culture. The cells have to undergo 
immortalization beyond the senescence check point in order to survive in-vitro. Different 
methods have been employed to immortalize cells in culture. Intact p16/Rb and p53/p21 
pathways are required to establish and maintain replicative senescence, thus 
inactivation of these pathways is necessary for immortalization. Papilloma virus 
oncogenes E6/E7, SV40 T-antigen can inactivate both p16/Rb and p53/p21 pathways 
and thus immortalize cells. hTERT, E6, RhoA, ZNF217, mutant p53 can immortalize p16 
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negative cells (Band, 2003; Dimri et al., 2005). These immortalized mammary cell lines 
can then serve as models to introduce different oncogenic alterations to study their 
behavior upon transformation. Cancer is a multistep process that involves genetic 
changes that allows the cells to become autonomous and proliferate in an uncontrolled 
manner. Acquisition of new mutations further endows the cells with the capacity to 
invade and spread to different places in the body. Different mammary transformation 
models have been derived where different oncogene combinations were expressed to 
transform the cells. Combination of SV40, hTERT, RAS have been shown to transform 
normal hMECs and upon injection in nude mice these cells also form metaplastic 
carcinomas (Elenbaas et al., 2001). Likewise, different cellular oncogenes combinations 
have been utilized to transform hMECs to study breast cancer pathogenesis (Bhagirath 
et al., 2015; Ince et al., 2007; Keller et al. 2012; Kendall et al., 2005).  
Besides these in-vitro methods, various in-vivo mouse models also shed light on 
the etiology of breast tumors. Generation of transgenic or knockout mouse models with a 
specific genetic alteration including TP53 knockout, transgenic PYMT, MYC, WNT1 
targeted specifically to mammary compartment using lineage specific promoters – 
MMTV, WAP-Cre, K14 or K8 has been another approach to study disease pathogenesis 
(Koren and Bentires-Alj 2015).  
 
1.4 Factors responsible for BC tumorigenesis 
1.4A Role of genetic alterations in BC pathogenesis 
More recent comprehensive analysis of large cohort of patient derived breast 
tumors have led to identification of various subtype specific gene alterations(TCGA 
2012, Banerji et al., 2012; Shah et al. 2012). Recurrence of different gene changes such 
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as mutations in PIK3CA, TP53, MAP3K1, RUNX1 or gene amplification/over-expression 
of ErbB2, loss of tumor suppressor PTEN, RB and association of these gene changes 
with different subtypes signifies an important gene alteration and subtype relationship 
(Banerji et al., 2012; Stephens et al. 2012). PI3KCA gene mutations comprise 45% of 
luminal-A, 29% luminal-B, 39% of ErbB2 over-expressing and 9% of basal subtype. 
Likewise TP53 mutations also has a recurrent pattern of occurrence, comprising of 32% 
of all breast tumors and highest rate of mutation in basal subtype (80%) and ErbB2 
subtype (70%) (Sorlie et al., 2001). Off these frequently observed mutations certain 
genetic changes function as the drivers of disease pathogenesis while others may occur 
as a result of evolution (Banerji et al., 2012; Stephens et al. 2012). Besides the 
predominance of somatic mutations in breast tumors, the hereditary breast cancer also 
constitute about 1-3% of total cases of breast cancer. Hereditary mutations in genes like 
BRCA1, BRCA2 is another example of genetically driven breast cancer where a single 
oncogene that has undergone mutations drives the tumor formation and its progression. 
Further investigation have shown that certain gene mutations correlate with resistance to 
therapy (Ellis et al. 2012). With advent of new gene sequencing methods and single cell 
analysis, several recent reports have identified and linked various mutations including 
those in PIK3CA or TP53 with poor clinical outcome or therapy resistance (Marcotte et 
al. 2016). Over-expression of oncogene ErbB2 and genes belonging to ErbB2 amplicon 
comprises of a whole BC subtype defined as ErbB2 over-expressing tumors. 
Identification of ErbB2 subtype was clinically important, as therapies targeting the 
receptor made their way to the treatment of tumors that have ErbB2 over-expression or 
amplification. Likewise tamoxifen treatment has been mainstay of breast cancer therapy 
to prevent advanced metastatic disease in patients with ER positive primary tumors.  
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Different oncogenes have been shown to confer transformation ability when over-
expressed in hMECs (Bhagirath et al., 2015; Elenbaas et al., 2001; Ince et al., 2007; 
Keller et al., 2012; Kendall et al., 2005). We over-expressed combinations of 
oncogene(s)/tumor-suppressor mRas/mp53/mPI3K, mRas/mp53/wtErbB2 or 
mRas/mp53/wtEGFR in immortalized stem progenitor cells previously developed and 
characterized in my mentor’s laboratory (Zhao et al. 2010) and assessed the contribution 
of each combination in driving BC pathogenesis. mp53 was included in the combination, 
owing to the predominance of TP53 mutations in primary breast tumors in patients 
(Sorlie et al., 2001). Similarly, Ras mutation has also been reported in BC patients and 
activation of Ras pathway and its effectors is now increasingly reported in patient 
derived tumors (McLaughlin et al., 2013; Wright et al. 2015). In support of this it has 
been recently shown that targeting mPI3KCA in different mammary epithelial cell 
compartment induces formation of distinct tumors, further emphasizing the differential 
effect of oncogene on cell types (Van Keymeulen et al. 2015).  
 
1.4B Role of cell type in BC pathogenesis 
Another likely factor that might contribute to the heterogeneity of breast tumors, 
are the cellular precursors in which the initiating genetic alterations occur. Normal 
mammary gland consists of hierarchy of cell populations including the normal adult stem 
cell, the progenitors and their differentiated progenies mainly the luminal and the 
myoepithelial cells. According to CSCs hypothesis a single stem cells undergoes 
transformation and give rise to tumor heterogeneity by its property of differentiation. 
Besides this another hypothesis has also been suggested to account for cellular 
heterogeneity in BC. It relies on the basis that cellular precursors at various stage of this 
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hierarchy have different susceptibilities to form tumors and that the nature of cell 
determines the subtype of tumors formed as a result (Visvader 2011). The idea gains 
some strength from the tumor microarray data derived from patients belonging to 
different subtypes where each subtype shows expression pattern inherently found in the 
normal cell lineages i.e. luminal or basal cells (Perou et al., 2000).  
Different markers have been utilized to identify and define the mammary stem or 
progenitor cells population within mammary gland. CD49f, CD44, CD24, EpCam are 
some of the markers that allowed identification of stem cells in mouse mammary glands. 
CD49fHigh, EpCAMpositive cells when isolated and transplanted in mice can fully 
reconstitute the entire mammary glands of the recipient mice (Shackleton et al., 2006; 
Stingl et al., 2006). Epithelial cells, are characterized by expression of various keratins. 
Stem cells in normal mammary gland are known to express several CKs including K5, 
K4, K14 and K19, and luminal cell express K8,18 ( Petersen and Polyak, 2010; Villadsen 
et al., 2007). The basal subtype of BC is shown to have presence of stem cell gene 
signatures, including high expression of CKs such as K5, K14, and K17, suggesting 
stem cell origin of this subtype (Sorlie et al., 2001). These tumors are less differentiated 
and are associated with worse clinical outcomes. Together these evidences suggest that 
basal like tumors could be resulting from transformation of a stem cell. In contrast to this, 
different studies from mouse models have shown that basal subtype can also arise from 
transformation of a luminal progenitor cell population (Lim et al., 2009; Molyneux et al. 
2010).  
Given the following associations we wanted to test the hypothesis whether it is 
the cell type and/or the oncogenic alteration that dictate the progression and onset of 
different subtypes of breast cancer. We utilized immortalized stem/progenitor cells 
(described below) that were isogenically derived from same donor, and that represented 
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different cell types in the hierarchy of mammary epithelial cells. We employed these 
basal bi-potent progenitor to also test the cancer stem cell and cell of origin hypothesis 
of BC. We over-expressed different combinations of oncogene(s)/tumor-suppressor 
(sub-type specific) to study their effect on transforming these cell types and in governing 
tumor pathogenesis from them. We found that both the nature of cell and transforming 
oncogene(s) influences the tumor pathogenesis. Tumor characteristics such as onset 
and incidence of primary or metastatic tumors varied with the oncogene combination that 
was over-expressed in a particular cell type (Chapter 2). We found that overall the 
metastatic abilities were dependent on the nature of cell type that gets transformed 
(Chapter 2, 3). In addition to the nature of cell type, we observed an important role of 
nature of oncogene on influencing tumor pathogenesis from a defined cell type 
(Bhagirath et al., 2015).  The observations and evidences from this study support the 
genetic as well as cellular basis for breast tumor heterogeneity.  
 
1.5 Immortalized mammary stem progenitor K5+/K19- and K5+/K19+ cells as 
models to study BC pathogenesis 
In order to study role of oncogene(s)/tumor-suppressor or the nature of cell type 
in mediating BC pathogenesis, we utilized hTERT immortalized mammary 
stem/progenitor cell lines designated as K5+/K19- or K5+/K19+. These two different 
isogenic cell lines that vary on the basis of CK19 from each other, were derived from 
same normal mammary reduction mammoplasty sample and co-express markers for 
stem, luminal or basal cell type such as – K8, K18, K5, K14, vimentin, EpCAM, p63 
(Zhao et al. 2010). As previously shown, both the cell lines possess the ability to self-
renew and differentiate into luminal or myoepithelial cell lines under proper differentiation 
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conditions. Most of the breast tumors highly express K19 (Bartek et al., 1985). K19+ 
hMECS are difficult to culture in-vitro (Gudjonsson et al., 2002). Thus these K19+ cell 
models developed and characterized in my mentors laboratory therefore provided as 
useful tools to better understand etiology of the disease. Furthermore, expression of K19 
is associated with poor prognosis in BC (Kabir et al. 2014).  CTCs derived from patients 
have been also shown to express CK19 (Xenidis et al., 2009). CK19 positive CTCs are 
indicator of relapsing or metastasized tumors in patients and their presence in patients 
undergoing chemotherapy indicates re-occurrence of the disease (Giuliano et al., 2014; 
Janni et al., 2016; Smerage et al. 2014). Together these findings emphasize the clinical 
importance of K19 expression in BC, and therefore make these cellular models very 
useful to study BC development.  
 
 
1.6 Role of mechanical forces in driving pathogenesis 
In addition to my study on role of cell types and oncogene combinations in driving 
BC pathogenesis, I also investigated the effect of matrix derived mechanical stiffness in 
mediating BC tumorigenesis from breast cancer cell lines, described briefly in Chapter 6. 
 The microenvironment plays an important role in driving mammary gland 
tumorigenesis. Human Mammary gland is a complex organ comprising of epithelial and 
stromal cells that are embedded in matrix of ECM proteins. Epithelial cells are 
surrounded by a dense matrix of extracellular matrix proteins, in which stromal fibroblast 
and immune cells are also interspersed. Normal mammary gland undergoes distinct 
morphological and functional changes in its epithelial and stromal compartment during 
different stages of its development. These changes are mediated by systemic hormones 
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and local growth factors that are secreted by the stromal cells (Wiseman and Werb, 
2002). In addition to these, the ECM surrounding the ducts/lobules also plays an 
important role in determining differentiation of epithelial cells and by itself can regulate 
gene expression changes (Li et al., 1987).  
ECM proteins provide the structural framework to the cells and serve as 
functional ligands to mediate mammary gland changes (Schedin and Keely, 2011; 
Wiseman and Werb, 2002). It has been shown that the matrix surrounding the epithelium 
provides mechanical inputs and influences epithelial cell morphogenesis and govern the 
formation of tubular structures from them (Alcaraz et al., 2008; Wozniak et al., 2003). 
Thus apart from the growth factor and hormone signaling the ECM mediated mechanical 
forces also play an important role in maintaining normal tissue homeostasis (Mammoto 
et al., 2013; Schedin and Keely 2011). Alterations in these normal homeostatic 
regulations are linked with the disease pathogenesis in an individual. The stromal 
compartment of mammary glands undergoes significant changes during tumor formation 
and gradual stiffening of the matrix occurs with progression of disease (Butcher et al., 
2009).  The cells in the tumor microenvironment regulate proliferation and survival of 
tumor cells via paracrine controls including the chemokines or growth factors such as 
CXCL12, CXCL14, HGF (Allinen et al., 2004; Scheel et al. 2011). Matrix stiffness was 
recently found to be associated with cancer associated fibroblasts (CAFs), where 
activation of mechano-regulated transcriptional factor Yes-associated protein (YAP) 
occurs in response to stiffer matrix, which further promotes a feed forward loop that 
sustains matrix stiffness and subsequent activation of CAFs (Calvo et al. 2013).  The 
stromal compartment of the tumor undergoes gene expression changes with the 
progression of disease specifically upregulating genes as MMPs that allow tumor cell 
invasion (Ma et al., 2009). Cancer associated fibroblast (CAFs) have been shown to 
13 
 
influence heterogeneity in tumors and have properties that facilitate invasion of primary 
tumor cells (Calvo et al. 2013). Stiffer microenvironment as a result of ECM crosslinking 
has been shown to contribute in breast tumorigenesis (Levental et al., 2009). An 
increase in matrix stiffness as a result of increase in ECM density has been further 
shown to promote tumorigenicity and leads to early onset of tumors in the MMTV.PyMT  
transgenic mice (Provenzano et al., 2008). In addition to this recent in-vitro findings have 
also shown that the increased matrix stiffness can promote proliferation and invasive 
behavior of human mammary epithelial cells (hMECS) (Paszek et al., 2005; Provenzano 
et al., 2009). Together these findings provide a compelling evidence for the important 
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BC is the second leading cause of cancer related deaths among women (Siegel et 
al. 2016). Molecular profiling of patient-derived tumors has revealed different subtypes 
based on gene expression signatures. The understanding of origin of various subtypes is 
highly important area of research considering that distinct subgroups result in significantly 
different outcomes, with the basal-like subtype correlating with the worst outcome, 
followed by claudin-low, ErbB2 over-expressing, luminal-B, normal-like and luminal-A 
subtype (Prat et al., 2010; Sorlie et al., 2001). The nature of genetic alterations affecting 
the cell may therefore play an important role in determining the pathology (i.e. latency, 
incidence etc.) of resulting tumors. Another important factor is the cell of origin in which 
the initiating oncogenic event takes place. The characteristic nature of a particular cell 
may determine its susceptibility towards oncogenic transformation as well as its ability to 
develop to primary and metastatic tumors.   
To understand the importance of cell type in determining tumor phenotype, in 
previous study investigators isolated two distinct hMECs by culturing normal mammary 
tissue under different conditions, transformed the cells with an identical set of oncogenes 
and injected these into mammary glands of immunocompromised mice. The injected cell 
lines gave rise to distinct tumors depending upon their differentiation states and developed 
lung metastasis in a cell type dependent manner (Ince et al., 2007). Similarly, another 
team of investigators showed that the origin of the transformed cell can determine the 
formation of tumor subtypes (Keller et al. 2012). Both studies support the idea that breast 
tumor subtypes may represent malignancies of biologically distinct cell types producing 
distinct disease entities. However, it is still not known whether the intrinsic differences in 
cell lines (susceptibility to transformation) may regulate the tumor phenotype by itself or 
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their oncogenic behaviors (transformation ability, tumor onset, incidence and metastatic 
capability) are also governed by the nature of genetic insults inflicted upon them.  
Here, we addressed these questions by subjecting two human mammary epithelial 
cell lines that exhibit defined differences but are cultured under identical conditions to 
transformation with defined oncogene combinations. Clonal cell lines corresponding to 
human mammary stem/progenitor cell types were previously isolated from a single healthy 
reduction mammoplasty specimen and immortalized using the catalytic subunit of human 
telomerase (hTERT). These two types of cell lines are designated as K5+/K19- or K5+/K19+ 
based on cytokeratin expression defining different lineage (Microarray accession no. 
GSE22580). Both of these cell types exhibit self-renewal and differentiate into both luminal 
and myoepithelial cells in vitro in defined medium (Zhao et al., 2010). Majority of breast 
cancers are carcinomas and K19 positive (Gudjonsson et al., 2002; Petersen and Polyak 
2010). Expression of K19 can be used as prognostic marker for breast cancer (Kabir et 
al. 2014) and presence of K19+ circulating tumor cells (CTCs) in patients before or after 
treatment is associated with poor disease free survival (Ignatiadis et al., 2007; Xenidis et 
al., 2009; Xenidis et al., 2007) . However, K19 positive normal mammary epithelial cells 
are difficult to isolate and immortalize in culture.  Thus, availability of K5+/K19+ and 
K5+/K19- mammary stem/progenitor cell lines generated in our laboratory provides a 
unique opportunity to assess their ability to serve as cells of origin for breast tumors and 
the impact of cell type versus oncogenes in tumor associated characteristics. 
Transformation of these two cell lines with different oncogene combinations was followed 
by extensive in vitro and in vivo analyses to demonstrate that both nature of cell type and 
genetic alterations contribute to the primary and metastatic behavior of tumors resulting 




2.2 MATERIALS AND METHODS 
 
Cell lines and retroviral/lentiviral infection 
Mutant p53R249S in pLENTI-6 (purchased from Addgene) along with Invitrogen 
packaging vector (ViraPowerTM Lentiviral Packaging MIX) were transfected into 293FT 
packaging cells.  Lentiviral supernatants were collected after overnight incubation in fresh 
DMEM media. TSA54 packaging cells were transfected with retroviral constructs, mutant 
H-Ras Q61L  in pBABE-hygro, wild type ErbB2 or wild type EGFR in pMSCV-puro vector or 
pMSCV GFP-luciferase vector (kind gift from Dr. Rakesh Singh, UNMC), together with PIK 
plasmid for packaging, and viral supernatants were collected  (as mentioned above for 
lentiviral). K5+/K19- and K5+/K19+ stem/progenitor cell lines (Zhao et al. 2010) were 
infected with viral supernatants to generate cell lines with different gene combinations 
followed by their selection in DFCI-1 medium (Band and Sager, 1989; Band et al., 1990) 
containing hygromycin (15ul/ml) (for mutant H-Ras), blasticidine (15ul/ml) (for mutant 
p53), puromycin (0.5ul/ml) (for wild type ErbB2 or EGFR). 
 
Antibodies  
The following antibodies were used for western blotting, immunofluorescence, 
flow-cytometry and IHC: Rabbit anti-human ErbB2 (sc-284), mouse anti-human p53 (DO-
1) (sc-126), mouse anti-human α-SMA (sc-32251), mouse anti-human vimentin (sc-6260) 
were from Santa Cruz Biotechnology. Mouse anti-human Ras (610001), mouse anti-
human EGFR (610016), mouse anti-human MUC1 (550486), rat anti-human CD49f 
(555734), FITC conjugated anti-CD24 (555427), PE-Cy5 conjugated anti- CD49f 
(551129), PE-conjugated anti-CD44 (555479), FITC conjugated anti-CD227 (MUC1-
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559774) and Alexa-488 conjugated E-Cadherin (560061) were from BD Bioscience. 
Mouse anti-claudin4 (329400) was from Invitrogen. Rabbit anti-human vimentin (clone 
SP20, RM-9120-S0) was from Thermo Scientific. Rabbit anti-human K5 (PRB-160P) was 
from Covance.  
 
Anchorage-independence growth assays 
 40,000 cells suspended in DFCI-1 medium containing 0.3% agarose were seeded 
in the top layer of each well of 6-well plates containing 0.6% agarose as a bottom layer. 
Each cell line was plated in triplicates. Colonies (>60 cells) were counted after 3 weeks 
after crystal violet staining.  
 
In vitro tumorsphere formation assays 
40,000 cells were plated per 2 ml in ultra-low attachment 6 well plates (Corning) in 
MEGM, as described previously by (Dontu et al., 2003). Each cell line had 6 replicates. 
Cells were fed with fresh medium on alternate days. Tumorspheres were counted under 
the microscope after 3 weeks of plating.  
 
In vitro differentiation assays 
Protocol used for matrigel assay has been described previously (Zhao et al., 2011; 
Zhao et al. 2012). Briefly, 1 million cells suspended in DFCI-2 (Band and Sager, 1989; 
Band et al., 1990) medium containing 2% matrigel were plated on P-100 dish coated with 
100% reconstituted basement membrane (matrigel from BD Biosciences).  After 12 days 
(alternate day feeding), matrigel was dissolved using dispase enzyme (BD Biosciences) 
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at 37oC for 1 hr, cells were counted and 1 million cells were stained with FITC conjugated 
anti-CD227 (MUC1) and PE-Cy5 conjugated anti- CD49f and analyzed by FACS.  
 
Xenograft transplantation assays for primary tumor formation 
6-8 weeks old immunodeficient NSG mice (purchased from Jackson laboratories) 
were injected with 1 million cells (not tagged with GFP-luciferase) in DFCI-1 medium 
mixed with matrigel in 1:1 proportion (Ince et al., 2007) in the fourth and ninth 
(contralateral) mammary glands. 4 mice were used for each combination. Tumor formation 
was assessed by palpation in the area of injection every week until 6 months. After six 
months, mice with or without tumors were sacrificed by CO2 inhalation followed by cervical 
dislocation. Tumors were excised, fixed with 10% neutral buffered formalin and processed 
to prepare paraffin-embedded tumor blocks that were then sectioned for IHC. 
 
Spontaneous metastasis formation assay 
GFP-luciferase tagged tumor cells were injected in mammary glands of NSG mice. 
10 mice were used for each combination. Mammary tumors formed after 
xenotransplantation of GFP-luciferase tagged tumor cells were surgically removed upon 
reaching 1000mm3 tumor size. Mice were routinely assessed for luciferase activity 
(peritoneal injection of 30mg/ml luciferin substrate) by IVIS machine to detect any primary 
tumor and metastasis formation at different sites. Any subsequent tumors formed were 






Tumor tissues were fixed in 10% NBF and processed into paraffin blocks. 4 μm 
sections were cut and stained with indicated antibodies. The standard staining procedure 
was performed using DAKO kit as per the manufacturer’s protocol (# K4007) and as 
described previously (Zhao et al.,2012). For IHC staining, tissue sections were incubated 
with primary antibodies (anti-K5, anti-MUC1, anti-vimentin, anti-α-SMA or anti-claudin4) in 
a hydrated chamber, followed by incubation with HRP-tagged secondary IgG against the 
primary antibodies and subsequently processed for nuclear staining and mounting of 
tissues. For double-immunofluorescence staining tumor sections were processed similarly 
and blocked with 10% goat serum for 1 hr.   These were then stained with rabbit anti-
vimentin, alexa 488 conjugated anti-E-cadherin, mouse anti- α-SMA or mouse anti-
claudin4 antibodies. Goat anti-rabbit alexa 594 and goat anti-mouse alexa 488 conjugated 
secondary antibodies (Invitrogen) were used for staining. The sections were mounted with 
anti-fade mounting media. Images were taken with fluorescence microscope (Zeiss 
axioplan 2 imaging microscope). 
 
Statistical Analysis 
Statistical analysis was performed to analyze the tumor and metastasis onset and 
incidence for each transfectant. Time to event outcomes (tumor latency and metastasis 
latency) were calculated using Kaplan-Meier plots and then compared among all four 
groups using log-rank tests.  If the overall p-value was significant, pairwise comparisons 
for each pair cell types were made with Sidak's correction. Tumor onset rate at 16-week 
follow up, lung and liver metastasis rate at 32-week follow up were compared using 




In vitro oncogenic transformation of K5+/K19- or K5+/K19+cells  
We have previously isolated and characterized two types of hTERT-immortalized 
mammary epithelial stem/progenitor cells that are designated as K5+/K19- or K5+/K19+ 
based on keratin expression (Microarray accession no. GSE22580, Supp. Table 1)(Zhao 
et al. 2010). We have reported previously that 100% of cells in these cell lines express 
designated keratins. These cell lines maintain self-renewal and are able to differentiate 
into both luminal and myoepithelial lineages upon culturing in defined medium (Zhao et al. 
2010). We introduced mRas, mp53, wtErbB2 or wtEGFR in different combinations in both 
cell types using retroviral/lentiviral infection (Figure 2.1). The choice of mp53, wtEGFR 
and wtErbB2 as transforming genes was based on their wide use in the literature and their 
well-known occurrence in breast tumors (Elenbaas et al., 2001; Ince et al., 2007; Keller et 
al., 2012; Ro et al., 1988; Sainsbury et al., 1987; Slamon et al., 1987). K5+/K19- and 
K5+/K19+ cells expression of various introduced genes was confirmed using western 
blotting (Figure 2.2A).  
To analyze the transforming ability of exogenously introduced oncogenes and to 
determine susceptibility of these two cell lines to oncogene induced transformation, we 
performed in vitro soft agar assays and assessed the ability of oncogene-transduced cell 
lines to proliferate in an anchorage independent manner. As expected, cells expressing 
vectors alone failed to exhibit anchorage independent growth.  In contrast, cells over-
expressing wtEGFR or wtErbB2 together with mp53 showed much larger colonies (Figure 
2.2C).  K5+/K19- and K5+/K19+ cells expressing mRas/mp53 together with either wtErbB2 
or wtEGFR showed anchorage independent growth (Figure 2.2B, 2.2C). Notably, total 
number of colonies in K5+/K19+ cells, were significantly higher than that of colonies 
obtained by transformed K5+/K19- cells (Figure 2.2B). These results demonstrate that in-
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vitro transformation ability of a cell type is dependent on intrinsic differences within the cell 
lines but not the oncogene combination over-expressed by the cells.  
























Figure 2.1: Generation of K5+/K19- and K5+/K19+ cells with different combination. 
Schematic representation of different oncogene combinations (single, double or triple) that 







Figure 2.2: Transformation of K5+/K19- or K5+/K19+ cells with different gene 
combinations.   
                            
 
               
 






Figure 2.2:  Transformation of K5+/K19- or K5+/K19+ cells with different gene 
combination.  A, K5+/K19- or K5+/K19+ cell lines over-expressing mutant p53, mutant Ras, 
wild type ErbB2 or wild type EGFR in single, double or triple oncogene combinations were 
analyzed by Western Blotting. β-actin was used as loading control. B, Anchorage 
independent growth assay of K5+/K19- and K5+/K19+ cells with vector or different gene 
combinations. Mean ±S.D of a representative experiment done in triplicate is shown. 
Three independent experiments were done. C, Representative images (magnification 
40X) of colonies from K5+/K19- and K5+/K19+ cells with vector or different oncogene 















Transformation of K5+/K19- or K5+/K19+cells leads to enrichment of stem cell 
population, and reduction in the proportion of differentiated cells   
It has been shown that loss of function of the tumor suppressor p53 enhances self-
renewal ability of mammary stem cells (Cicalese et al., 2009). Similarly, other studies have 
shown that EGFR (Brandt et al., 2000; Deugnier et al., 2002), ErbB2 (Nair et al. 2014)  or 
Ras (Cerrito et al., 2004; Jehn et al., 1992) play an important role in mammary stem cell 
self-renewal. We have previously shown that upon immortalization (pre-neoplastic 
transformation) with certain oncogenes, the stem/progenitor cell lines lose their ability to 
differentiate into myoepithelial cells (Zhao et al. 2010). Therefore, in this study we 
evaluated the impact of over-expression oncogene combinations on stem cell self-renewal 
and differentiation. We assessed the ability of oncogene over-expressing vs. vector control 
mammary stem/progenitor cell lines to form tumorspheres in ultra-low attachment plates, 
a commonly used assay to determine cancer stem cell self-renewal abilities (Charafe-
Jauffret et al., 2009; Dontu et al., 2003; Mani et al., 2008; Zhang et al., 2008).  Vector 
expressing cells showed formation of small spheres (<200 μm) and were not counted 
(Figure 2.3C). However, both cell types overexpressing single or double oncogene 
combinations showed tumorsphere formation as compared to control cells (Figure 2.3A, 
2.3E). Notably, cells expressing the triple combinations of oncogenes exhibited a 
significant increase in number of tumorsphere (>200 μm in size) formed (Figure 2.3A-D). 
Both the transformed K5+/K19- or K5+/K19+ cells formed secondary tumorspheres upon re-
plating (Figure 2.3B, 2.3C) and the efficiency for tertiary tumorsphere formation was  
substantially enriched for cells over-expressing oncogene combination 
mRas/mp53/wtEGFR (Figure 2.3C) demonstrating increased self-renewal capabilities of 




Figure 2.3: In-vitro self-renewal of K5+/K19- or K5+/K19+ cells over-expressing 
different oncogenes 
                           
                                       
                                    
                               










Figure 2.3: In-vitro self-renewal of K5+/K19- or K5+/K19+ cells over-expressing 
different oncogenes. For tumorsphere-formation assay indicated cell lines were cultured 
in low-attachment plates in MEGM media for 3 weeks. A) Primary tumorshperes were 
trypsinized and cultured to generate B) secondary or C) tertiary tumorspheres. Spheres 
≥200μm were quantified. Mean +/- SD of a representative experiment done in 6 replicates 
is shown. D), E) Representative images (magnification 4X) of tumorspheres from K5+/K19- 
and K5+/K19+ cells with vector or  different oncogene combinations (single, double or 
















Previously, we showed that both K5+/K19- and K5+/K19+ cell types express high 
levels of CD49f and CD44, and variable expression of CD24 where intermediate (inter) 
and high levels of CD24, reflects more differentiated progenitor cells (Zhao et al.,2010; 
Zhao et al. 2011). We therefore used a combination of these markers for FACS analysis 
to assess the relative levels of stem/progenitor cells vs. differentiated cells in various triple 
transformed derivatives. Notably, we observed a significant decrease in CD24inter and 
CD24Hi population (Figure 2.4A, 2.4B, 2.5A, 2.5B) in both transformed stem/progenitor cell 
lines in comparison with the vector-expressing cells, indicating an enrichment of stem cell 
population in both cell types upon transformation.   
As previously shown, K5+/K19- and K5+/K19+ mammary stem/progenitor cell lines 
are bi-potent stem/uncommitted progenitors and are able to differentiate into both luminal 
and myoepithelial cells under appropriate differentiating conditions (Zhao et al. 2010). 
Furthermore, when grown in 3D matrigel culture and subjected to differentiating media 
DFCI-2, the stem/progenitor cells are preferentially induced into luminal differentiation  
(Zhao et al. 2010). Notably, when we subjected K5+/K19- and K5+/K19+ cells expressing 
triple oncogene combinations to differentiation using in-vitro 3D matrigel culture, we 
observed an increased CD49f+ (marker for stem cell) fraction (97% vs. 86% for K5+/K19- 
and 96% vs. 92% for K5+/K19+) and decrease in MUC1+ (marker for luminal 
differentiation) fraction (0.4%,0.1% vs. 0.9% for K5+/K19- and 0.5%,0.2% vs. 1.2% for 
K5+/K19+) in transformed lines vs. their controls (Figure 2.6A, 2.6B). These results indicate 
that oncogene-mediated transformation of mammary stem/progenitor cells reduces their 
ability to differentiate. Taken together, these results demonstrate an increase in stem cell 





Figure 2.4: Expression of different stem cell markers in K5+/K19- or K5+/K19+ 
expressing different combinations  
               
 
               
Figure 2.4: Expression of different stem cell markers in K5+/K19- or K5+/K19+ 
expressing different combinations. Vector or transformed (A) K5+/K19- or (B) K5+/K19+ 
cells were stained with stem cell markers CD49f, CD44 and CD24 and analyzed by Flow 
Cytometry. Dot plot analysis of cell population expressing CD44/CD24 (upper panel) and 






Figure 2.5: Expression of different stem cell markers in K5+/K19- or K5+/K19+ 
expressing different combinations. 
 
       
 
        
 
Figure 2.5: Expression of different stem cell markers in K5+/K19- or K5+/K19+ 
expressing different combinations. A and B. K5+/K19- (A) or K5+/K19+ (B) cells over-
expressing single (mp53, mRas, wtErbB2 or wtEGFR) or double (mp53/wtErbB2 or 
mp53/wtEGFR) were stained with stem cell markers CD49f, CD44 and CD24 and 
analyzed by Flow Cytometry. Dot plot analysis of cell population expressing CD44/CD24 
(upper panel) and CD49f/CD24 (Lower panel). Change in CD24 cell population is seen in 






Figure 2.6: In-vitro differentiation ability of transformed K5+/K19- or K5+/K19+cells. 
 
        
 
          
 
Figure 2.6: In-vitro differentiation ability of transformed K5+/K19- or K5+/K19+ cells 
A) and B). Control or transformed K5+/K19-(A) or K5+/K19+ (B) cells were grown in DFCI-
2 (differentiation) medium in Matrigel. Acini were trypsinized and stained with PE-Cy5 







Oncogene-transformed K5+/K19- and K5+/K19+ cells produce mixed tumors in NSG 
mice 
Given the in-vitro capabilities of both cell types to exhibit anchorage independence 
and enhanced tumorsphere formation when  transformed (Figure 2.2B, 2.2C and Fig. 2.3), 
we assessed their ability to form tumors upon orthotopic implantation in the mammary 
glands of immunocompromised NSG mice, as a proof of full oncogenic transformation. 
Triple (mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR) oncogene transformed K5+/K19- 
and K5+/K19+ cells were injected orthotopically in mice mammary glands. As expected, 
none of the mice implanted with control vector cells or those with double oncogene 
combinations produced tumors, while all the triple oncogene transformed K5+/K19- and 
K5+/K19+ cells gave rise to tumors in mice. Histologically, tumors arising from triple 
oncogene combinations in K5+/K19- and K5+/K19+ cells appeared distinct from each other. 
Tumors arising from transformed K5+/K19- cells exhibited predominance of spindle-like 
tumor cell morphology while those arising from transformed K5+/K19+ cells resembled 
adenocarcinomas (Figure 2.7). These differences in the tumor phenotype are consistent 
with previous findings that biological differences in cell types can give rise to distinct 
histological subtypes of tumors (Ince et al., 2007; Keller et al. 2012). We further observed 
that all tumors exhibited intra-tumoral heterogeneity as seen by the expression of various 
markers including MUC1 (for luminal differentiation), K5 (for stem-progenitor/basal), 
vimentin (for stem-progenitor/basal/myoepithelial), α-SMA (for myoepithelial) and claudin4 
(for claudin-low) (Figure 2.8, 2.9). In order to confirm that the claudin-low component within 
the tumors with mixed phenotype was derived from the transformed human 
stem/progenitor cells, we performed double immunostaining of these tumors with human 
specific anti-vimentin together with anti-α-SMA, anti-E-cadherin or anti-claudin4 (Fig. 
2.7A-C). K5+/K19- cells over-expressing wtErbB2 combination predominantly gave rise to 
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tumors with high claudin-low (spindle like, α-SMA+ ,vimentin+, claudin4-) and less basal 
(K5+) characteristics, whereas the same cells over-expressing wtEGFR combinations 
formed tumors with mixed basal, luminal and claudin-low phenotype (Figure 2.7, 2.8, 2.9). 
Similarly tumors arising from K5+/K19+ cells  over-expressing wtErbB2 combination 
showed more luminal and basal characteristics, whereas those derived by wtEGFR 


















Figure 2.7: Transformed K5+/K19- or K5+/K19+ cells give rise to distinct tumors. 
                   
                                                             
                                                     
Figure 2.7: Transformed K5+/K19- or K5+/K19+ cells give rise to distinct tumors. A, 
Representative images of H&E staining of tumor sections (magnification 20X) from 
K5+/K19- and K5+/K19+ cells over-expressing mRas/mp53/wtErbB2 (upper panel) or 







To exclude the possibility of mouse mammary gland contribution, we used human 
specific vimentin antibody to confirm that the tumors were derived from the injected human 
cells. Vimentin antibody used here is highly specific for human cells as it neither detects 
vimentin protein in western blotting using mouse fibroblasts (Figure 2.10) nor does it stains 
mouse mammary gland (Figure 2.11A, 2.11B). Interestingly, staining of tumor sections 
from mice injected with K5+/K19+ cells over-expressing wtEGFR combination showed both 
infiltrating ductal carcinoma and well-formed ductal structures with varying degrees of 
hyperplasia. The hyperplastic structures had a well-defined outer α-SMA-positive, 
vimentin positive (myoepithelial) and inner MUC1 positive (luminal) staining pattern (Fig. 
2.11A, 2.11B), indicative of the ability of human K5+/K19+ cells to differentiate into both 
myoepithelial and luminal cells in vivo. All tumors from transformed K5+/K19- and K5+/K19+ 
stem/progenitor cells were ER-negative (data not shown) consistent with the ER-negative 












Figure 2.8: Transformed K5+/K19- or K5+/K19+ cells give rise to distinct tumors. 
 
          
 
Figure 2.8: Transformed K5+/K19- or K5+/K19+ cells give rise to distinct tumors. 
Images from different tumors at magnification 20X.  Immunohistochemical staining of 
tumor sections with anti-CK5 (Basal/Stem), anti-MUC1 (Luminal), anti-αSMA 





Figure 2.9: Transformed K5+/K19- or K5+/K19+ cells give rise to distinct tumors. 
 
                            
                                                         






Figure 2.9: Transformed K5+/K19- or K5+/K19+ cells give rise to distinct tumors.  
Representative image of  tumors from K5+/K19- orK5+/K19+ cells double immunostained 
with A) anti-αSMA (green) and anti-vimentin (red) show presence of claudin-low 
(SMA+/vimentin+) areas within different tumors.  Same tumor sections double 
immunostained with B) E-Cadherin (green) and vimentin (red) show presence of luminal 
like (E-Cadherin+) areas within different tumors and C) with anti-claudin4 (green) and anti-
Vimentin (red) show presence of claudin-low (claudin4-/Vimentin+) areas within different 
tumors. DAPI (blue) shows nucleus. 
 
 













Figure 2.10. Human specificity of vimentin antibody. 
                             
 
Figure 2.10. Human specificity of vimentin antibody. Western blot.  Cell lysates from 
transformed K5+/K19+ cells, mouse and human derived fibroblast cells and breast cancer 
cell line T47D were probed with human specific vimentin antibody and analyzed by 









Figure 2.11: Transformed K5+/K19- or K5+/K19+ cells retain stem cell characteristics 
in-vivo 
 









Figure 2.11: Transformed K5+/K19- or K5+/K19+ cells retain stem cell characteristics 
in-vivo. A, Immunostaining with lineage specific markers of tumors and mammary duct 
like structures with varying degree of hyperplasia originating from K5+/K19+ cells over-
expressing mRas/mp53/wtEGFR. Yellow arrowheads with H indicate human mammary 
ductal structures, white arrowheads with M indicate mouse mammary ducts and arrow 
with T shows tumor. B, Immunofluorescence staining of the same tumor section with  anti-
vimentin (red), anti-αSMA (green) antibodies at magnifications 20X (left panel) and 40X 
(right panel). White arrowhead indicate mouse ductal structure, yellow arrowheads 















Both oncogene and cell type contribute to tumor development and progression in 
NSG mice  
Mice injected with cells over-expressing triple oncogene combinations developed 
tumors consistently (Table 2.1, 2.2). Notably, tumors arising from mRas/mp53/wtEGFR 
over-expressing K5+/K19- cell line had a statistically significant longer latency and lower 
tumor incidence than those arising from other cell lines tested (Figure 2.12A, Table 2.4). 
The average tumor latency was 20 weeks for K5+/K19- cell with mRas/mp53/wtEGFR  and 
11.75 weeks for K5+/K19- over-expressing mRas/mp53/wtErbB2 (Figure 2.12A, Table 2.5) 
. Despite the longer primary tumor latency wtEGFR combination had a higher lung 
metastasis incidence (Table 2.3, Figure 2.12B, 2.12C, Table 2.6) as compared to wtErbB2 
in K5+/K19- cell line and unique liver metastasis (Figure 2.12E, Table 2.3, Table 2.7).  
These results support the conclusion that different oncogenes can drive distinct oncogenic 
and metastatic potential in same cell type. On the other hand, we observed K5+/K19+ cell 
line over-expressing mRas/mp53/wtEGFR had a low primary tumor latency as compared 
to K5+/K19- with same oncogene combination (Figure 2.12A, Table 2.1, 2.2, 2.5) and high 
tumor incidence (Table 2.8) as compared to all other cell lines tested.  More significantly, 
K5+/K19+ cell line over-expressing either mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR 
had statistically significant lower lung metastasis latency (Figure 2.12B, Table 2.9) as 
compared to K5+/K19- with mRas/mp53/wtErbB2, higher lung metastasis incidence (Table 
2.3, 2.6) and bigger metastatic tumors (Figure 2.12D) as compared to K5+/K19- cells over-
expressing either of the oncogene combinations, indicating that the nature of cell type also 
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Figure 2.12: In-vivo tumor and metastasis formation from transformed K5+/K19- or 
K5+/K19+ cells. 
 
             
 
                                                          
                                                
                                                  








Figure 2.12: In-vivo tumor and metastasis formation from transformed K5+/K19- or 
K5+/K19+ cells. A, Kaplan-Meier plot for probability of no tumor in mice injected with 
K5+/K19- and K5+/K19+ cells over-expressing mRas/mp53/wtErbB2 or 
mRas/mp53/wtEGFR from the second experiment. B, Kaplan-Meier plot for probability of 
no metastasis in above mentioned mice. C, Representative image of mice with or without 
lung metastasis as shown by IVIS luciferase imaging. D, Representative image of lung 
metastatic lesions formed by different cell types with either mRas/mp53/wtErbB2 (upper 
panel) or mRas/mp53/wtEGFR (Lower panel). E, Representative image of liver metastasis 
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Table 2.4 Log-rank test for time (in weeks) taken to form tumors in mice (n=10 each). 
 
 
K5+/K19- mRas/mp53/wtEGFR group had longer tumor latency compared with K5+/K19- 
mRas/mp53/wtErbB2, K5+/K19+mRas/mp53/wtErbB2, and K5+/K19+ 










Table 2.5. Lung metastasis rate at 32-week follow up  
 
 
There was indication of a difference among four groups with regard to lung metastasis 
rate at 32-week follow up  (p=0.03).The K5+/K19- mRas/mp53/wtErbB2 group had lowest 
lung metastasis rate and K5+/K19+ mRas/mp53/wtErbB2 and K5+/K19+ 


















There was indication of a difference among four groups with regard to liver metastasis rate 
at 32-week follow up (p=0.03). The K5+/K19- mRas/mp53/wtEGFR group had highest liver 













Table 2.7.  Tumor incidence rate at 16-week follow up. 
  
 
There was indication of a difference among four groups with regard to tumor onset rate at 
16-week follow up (p=0.01).The K5+/K19- mRas/mp53/wtEGFR  group had lowest tumor 














Table 2.8.  Log-rank test for time (in weeks) taken to form metastasis in mice 
 
K5+/K19- mRas/mp53/wtErbB2 group took longer time to develop the first metastasis 
compared with K5+/K19+ mRas/mp53/wtErbB2 (median survival time in weeks: 32 vs. 29,  
Sidak adjusted p-value: 0.02), and K5+/K19+ mRas/mp53/wtEGFR (median survival time 










Diversity in breast tumors is multifactorial. Classification of tumors in to various 
subtypes emphasizes the important role of genetic mutation/overexpression in 
characterizing a tumor (Perou et al., 2000; Sorlie et al., 2001). Besides, the type of cell in 
which a particular genetic event occurs is another important factor that may determine the 
phenotype of tumors (Ince et al., 2007; Keller et al. 2012). While it is likely that tumor 
heterogeneity is of multifactorial origin, there is now wider acceptance of the idea that 
breast cancers exhibit a stem cell hierarchy (Al-Hajj et al., 2003; Liu et al., 2010; Reya et 
al., 2001).Thus, one aspect of cellular diversity in tumors is thought to reflect the relative 
contributions to tumor mass of cells representing various points in the stem cell program. 
However, experimental support for the relative importance of cell types from which tumors 
arise versus the oncogenic events themselves has been difficult as suitable cellular 
models have not been available. Here, we have transformed immortal human mammary 
stem/progenitor cell lines with breast cancer-relevant cellular oncogenes to address these 
issues. Our analyses show that both the cell of origin as well as makeup of oncogenic 
events are important factors that shape the phenotype, oncogenicity as well as the 
metastatic behavior of a particular tumor.  
We utilized two unique, well characterized normal human mammary 
stem/progenitor cell lines originating from a single donor that exhibit stable differences in 
keratin 19 expression as well as  other genes (Microarray accession no. GSE22580, Supp. 
Table 1) and are, designated as K5+/K19- and K5+/K19+.  These cells can be propagated 
in culture as they have been rendered immortal with hTERT (Zhao et al. 2010). The cells 
remain in an undifferentiated state when grown in DFCI-1 medium but can be predictably 
induced to differentiate into myoepithelial and luminal lineages when cultured in 
differentiating media, thereby demonstrating their bi-potent nature (Zhao et al. 2010). 
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Although majority of breast cancers are K19+ the mechanistic insights of this observation 
has not been addressed much in the literature. A correlative study suggested K19+ breast 
cancers exhibit poor prognosis (Kabir et al. 2014). Further studies have demonstrated, 
K19+ CTCs in breast cancer patients are associated with poor disease-free survival 
(Ignatiadis et al., 2007; Xenidis et al., 2009). Additionally, treatment with trastuzumab can 
eliminate chemotherapy resistant K19 positive CTCs and can lead to reduction in disease 
recurrence and increased disease-free survival, suggesting K19 positive CTCs are 
associated with poor disease outcome (Georgoulias et al. 2012) . Another study 
demonstrated presence of CTCs with K19+ expression during tamoxifen treatment is 
associated with increased risk of disease relapse (Xenidis et al., 2007). Taken together, 
these studies underscore the importance of studying K19+ transformed breast cell lines.  
Selection of transforming genes was based on a combination of relevance to 
human breast cancer and experimental ease. Choice of mp53, wtErbB2 or wtEGFR 
reflects a plethora of evidence that demonstrates a prevalent role of these in the 
pathogenesis of human breast cancers (Ro et al., 1988; Sainsbury et al., 1987; Slamon et 
al., 1987).  For example EGFR is overexpressed in basal subtype (Livasy et al., 2006), 
ErbB2 is overexpressed in ErbB2+ subtype (Slamon et al., 1987) while p53 is known to 
be frequently mutated in most breast cancer subtypes. While selection of mutant Ras 
oncogene was based on evidence from a number of investigators, that mutant active Ras 
functions as a potent collaborator in full transformation of human mammary epithelial cells 
in in vitro, as well as in mouse mammary orthotopic tumorigenesis models (Elenbaas et 
al., 2001; Ince et al., 2007; Keller et al., 2012; Kendall et al., 2005). Notably, although the 
frequency of Ras mutations is low in breast cancer (about 5% of total breast cancer cases), 
activation of Ras pathway is frequently seen in breast tumors and in several breast cancer 
cell lines (Janes et al., 1994; von Lintig et al., 2000). In addition to overexpression of 
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upstream receptor tyrosine kinases EGFR and ErbB2 that are well known to activate Ras 
pathway as part of the oncogenic signaling program (Janes et al., 1994; von Lintig et al., 
2000), recent evidence has identified other oncogenic events that can activate the Ras 
pathway in breast cancer, including recurrent mutations in MAP3K1 (Banerji et al.,2012; 
Stephens et al. 2012) and mutations of  RASAL2,  a RasGAP gene that functions as 
negative regulator of Ras (McLaughlin et al. 2013). 
When we overexpressed defined combination of three oncogenes we observed an 
efficient anchorage independent growth in soft agar assays (Figure 2.2B, 2.2C). 
Consistent with the in-vitro transformation (assessed by their ability to be anchorage 
independent) cells with triple oncogene combinations gave rise to tumors when 
orthotopically-implanted into mammary glands of immunocompromised mice.  Significant 
differences in the onset of primary tumors and lung metastasis was observed when 
comparing different cell lines and different oncogene combination (Table 2.1-2.9). 
K5+/K19+ cells had a higher susceptibility towards transformation (Figure 2.2B) and had 
an early onset of primary tumors as well as lung metastasis as compared to K5+/K19- 
(Table 2.1, 2.2, 2.3, 2.5, 2.9 Figure 2.12) suggesting that overall these K19+ 
stem/progenitors are more prone to transformation. This may be the likely reason why 
more than 90% of human breast tumors are K19 positive (Gudjonsson et al., 2002; 
Petersen and Polyak 2010). This indicates that the cell type in which tumor initiates plays 
an important role in development and progression of tumor. In addition we found that, 
presence of EGFR instead of ErbB2 in the triple oncogene combination potentially drives 
an early lung metastasis and give unique liver metastasis from same cellular precursor i.e 
K5+/K19- (Table 2.3, 2.7) suggesting the significant effect of an oncogene on pathogenicity 
of tumor. Most of the basal like breast tumors express or over-express EGFR and have a 
high propensity for metastasis. There are clinical reports that have shown an up-regulated 
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EGFR expression in both primary and metastatic tumors (Hicks et al., 2006; Hohensee et 
al. 2013). However the exact mechanism by which EGFR function in promoting metastasis 
is not very well understood. Besides the tumor latency and metastasis progression we 
also observed cell type dependent effect on primary tumor histology (Figure 2.7, 2.8). 
Together these data support the idea that both oncogenes and cell type in which 
oncogenesis was initiated contribute to key tumor traits, such as latency and incidence. 
The mammary stem/progenitor cell lines utilized here are endowed with self-
renewal and bipotent differentiation capabilities (Zhao et al. 2010), allowing us to assess 
the impact of  oncogenic transformation on their ability to self-renew and give rise to 
differentiated progeny. We present evidence that introduction of oncogenes into these 
stem/progenitor cell lines enhances their self-renewal capability as assayed using 
tumorsphere assays (Figures 2.3) and reduces their differentiation potential (Figure 2.7). 
It is likely that these traits are important in the tumorigenic phenotype as we observe these 
only upon oncogene overexpression. This is consistent with previous findings using in vivo 
mammary tumorigenesis models that tumor cells with loss of p53 function or 
overexpression of ErbB2 exhibit increased self-renewal (Cicalese et al., 2009), and that 
activated Ras or over-expression of EGFR inhibit normal mammary gland differentiation 
(Brandt et al., 2000; Cerrito et al., 2004).    
Tumors in mice implanted with oncogene-transformed K5+/K19+ or K5+/K19- cell 
lines exhibited substantial cellular heterogeneity with respect to the components of 
luminal, basal and/or claudin-low like cells, which were assessed by the expression of 
luminal and myoepithelial cell specific markers. Oncogene-transformed derivatives of 
K5+/K19+ cells predominantly give luminal adenocarcinoma phenotype, whereas tumors 
arising from transformed K5+/K19- cell type produced more metaplastic carcinomas 
(Figure 2.7). Thus, our results clearly show that differences in cell of origin can 
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substantially influence the tumor phenotype, consistent with previous reports where 
primary human mammary epithelial cells propagated in different culture conditions were 
used for transformation (Ince et al., 2007).  
In conclusion, using a unique set of stem/progenitor hMECs, we demonstrate that 
both the cell type in which oncogenic events are initiated and the nature of oncogenic 
events contribute to breast cancer histology, onset and incidence of primary and 
metastatic tumor. These unique cellular models should be highly useful to further explore 
the mechanisms that contribute to cellular heterogeneity in breast cancer as well as other 
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Tumor progression is a multi-factorial process. The extent of disease progression 
may vary from one patient to another. Several cell intrinsic and extrinsic factors 
contribute to the dissemination of primary tumor cells and their colonization at the 
metastatic sites (Thiery et al., 2009). Subtype classification of breast tumors has allowed 
for categorization of different tumors in to those with good or poor prognosis. The 
prediction for patient survival is mainly based on the gene signatures of the tumors as 
well as the mutational status of important oncogenes/tumor–suppressor such as p53, 
PTEN, PI3K within the tumor (TCGA 2012, Sorlie et al., 2001) . Basal subtype of breast 
cancer that is associated with the worst survival outcomes, have gene signatures 
associated with higher cell proliferation (Banerji et al., 2012; Perou et al., 2000; Sorlie et 
al., 2001). On the other hand, tumors belonging to luminal subtype express genes for 
luminal differentiation and overall have a good survival (Perou et al., 2000; Sorlie et al., 
2001) . Furthermore, gene expression analyses of patient derived primary tumors also 
possess a strong predictive value in evaluating disease progression and distant 
metastasis (Minn et al., 2005; van 't Veer et al., 2002) . Presence of disseminated or 
circulating tumors cells (CTCs) in patient’s blood circulation, serve as early predictor for 
metastatic disease  (Giuliano et al. 2014) and are strong prognostic indicator of disease 
free-survival and drug therapy response (Bidard et al., 2010; Janni et al., 2016; Smerage 
et al. 2014). CTCs have been shown to express CK19 mRNA and serve as an 
independent predictor for disease free survival and their presence in patients undergoing 
chemotherapy suggests likelihood of a relapsing disease or metastasis (Georgoulias et 
al.,2007; Ignatiadis et al., 2007; Xenidis et al., 2009) . This association emphasizes an 
important characteristic of disseminated tumor cells, therefore understanding the 
pathogenesis of disease from K19+ cellular precursor becomes important. 
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As previously described in Chapter 2 (Bhagirath et al. 2015), we developed 
primary and metastatic tumors models from K5+/K19- or K5+/K19+ stem/progenitor cells 
transformed by either mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR. We observed that 
both the nature of cell type i.e. either K5+/K19- or K5+/K19+ cells and the introduced 
oncogene combination affected the phenotype, latency and incidence of primary and 
metastatic tumors in mice. Particularly, transformed K5+/K19+ cells overall have a 
higher anchorage independent growth and metastasis incidence as compared to 
transformed K5+/K19- cells (Table 2, 3 chapter 2). Given the prognostic relevance of 
K19 expression in metastatic disease progression and its expression in CTCs, it will be 
important to study the factors associated with K19+ tumor models that we have 
generated and compare them with their corresponding K19- derivatives. In the present 
chapter, we describe gene expression changes that are associated with the different 
tumors and identify gene alterations that most likely predict poor survival outcomes.   
In conclusion, we observed that the tumors from transformed K5+/K19- cells had 
an up-regulated EMT gene signature, particularly in those from K5+/K19- 
mRas/mp53/wtErbB2 combination. Transformed K5+/K19+ with oncogene combination 
mRas/mp53/wtEGFR have gene changes associated with breast cancer metastasis, that 
explain the early onset and higher frequency of lung metastasis as observed previously 







3.2 MATERIALS AND METHODS  
RNA extraction and Affymetrix Chip-Based Microarray Analyses  
Liquid nitrogen snap frozen tumor tissues were homogenized to powder using 
mortar and pestle. Total RNA was isolated from tumors using the TRIzol reagent 
(Invitrogen). A total of 200 ng of total RNA from primary or metastatic tumors was 
reverse transcribed and cRNA generated per manufacturer’s instructions using the 
Affymetrix 3′ IVT Express labeling kit (Affymetrix). Resultant cRNA probes were 
hybridized to the Affymetrix human U133 Plus 2 genome array per manufacture’s 
suggestions and the chips were scanned using a GeneChip 3,000 6G scanner through 
UNMC DNA Microarray Core Facility. The resultant datasets were scaled using GCOS 
software, evaluated with respect to quality assurance parameters to include background, 
hybridization kinetics, and reverse transcription efficiency. Affymetrix comparison 
analysis software was used to determine fold-change differences between samples. 
 
Antibodies  
The following antibodies were used for immunofluorescence and 
immunohistochemistry (IHC): mouse anti-human α- SMA (sc-32251), mouse anti-human 
vimentin (sc-6260) were from Santa Cruz Biotechnology. Mouse anti-human MUC1 
(550486) and mouse Alexa-488 conjugated E-Cadherin (560061) were from BD 








Metastatic lung tumors were fixed in 10% Neutral Buffered Formalin (NBF) and 
processed into paraffin blocks. 4 μm sections were cut and stained with indicated 
antibodies. The standard staining procedure was performed using DAKO kit as per the 
manufacturer’s protocol (# K4007) and as described in (Zhao et al. 2010). For IHC 
staining, tissue sections were incubated with primary anti-MUC1antibody in a hydrated 
chamber, followed by incubation with HRP-tagged secondary IgG against the primary 
antibodies and DAB solution and subsequently processed for nuclear staining with 
hematoxylin and mounting of tissues. For double-immunofluorescence staining tumor 
sections were processed similarly and blocked with 10% goat serum for 1 hr. These 
were then stained with rabbit anti-vimentin, alexa 488 conjugated anti-E-cadherin or 
mouse anti- α-SMA antibodies. Goat anti-rabbit alexa 594 and goat anti-mouse alexa 
488 conjugated secondary antibodies (Invitrogen) were used for staining. The sections 
were mounted with anti-fade mounting media. Images were taken with fluorescence 
microscope (Zeiss axioplan 2 imaging microscope). 
 
Ingenuity Pathway analysis 
Top 50 differentially up or downregulated genes from different combination were 
added to IPA dataset and analyzed for networks, canonical pathways, disease and 
molecular functions associated with each combination. Analysis was done as previously 




Quantitative Real-time PCR  
1 μg of total RNA was used for reverse transcriptase reaction using 
SuperScriptTM II reverse transcriptase (Invitrogen). Real-time PCR quantification was 
performed in triplicate using SYBR Green PCR master mix (Applied Biosystems) and the 
primers listed in Table 3.1. Expression levels were normalized against β-actin RNA 
























Differential gene expression changes in xenograft tumors formed by transformed 
K5+/K19- or K5+/K19+ cell lines 
In order to study the molecular basis for differences in tumor characteristic, we 
performed microarray analysis of the primary tumor from all 4 groups (K5+/K19- 
mp53/mRas/wtErbB2, K5+/K19+ mp53/mRas/wtErbB2, K5+/K19- mp53/mRas/wtEGFR 
and K5+/K19+ mp53/mRas/wtEGFR) and lung metastatic tumor derived from K5+/K19+ 
mp53/mRas/wtEGFR. Metastatic tumors from K5+/K19+ mp53/mRas/wtEGFR had a 
significantly shorter latency and higher incidence and were therefore chosen for the 
analysis (Table 3, 4 chapter 2). These tumors were generated from the xenograft assay 
as described previously in Chapter 2. To delineate the respective contributions of cell 
type or oncogene in determining tumor pathogenesis, we assessed the gene expression 
changes in different combinations (Figure 3.1).  
Differentially expressed genes were assessed by deriving fold change in 
expression from the microarray data. Table 3.2-3.6 shows top 10 genes that were up- or 
down- regulated in different combinations (Figure 3.1). Neurofilament light polypeptide 
NEFL was found to be highly expressed in tumors formed by K5+/K19- over-expressing 
mp53/mRas/wtErbB2. Different studies have shown that NEFL gene hypermethylation or 
loss of NEFL mRNA is linked to disease progression in BC (Calmon et al.,2015; Li et al. 
2012). Interestingly, gene expression of S100 proteins- S100A7, S100A8, S100A9, 
S100AP were also observed to be decreased in these tumors (Table 3.2, 3.3). S100 
proteins are most commonly deregulated protein in different cancers including breast, 
prostate, lung, pancreatic or colorectal cancers and are involved in process of growth 
and metastasis in tumors (Bresnick et al. 2015). Low expression of these genes and 
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over-expression of NEFL in K5+/K19- mp53/mRas/wtErbB2 tumors, provide some 
explanation for the overall lower incidence of metastasis in these tumors (Table 3, 
Chapter 2). Additionally, K5+/K19- mRas/mp53/wtErbB2 tumors had an up-regulated 
expression of collagen mRNA including COL15A and COL3A as compared to tumors 
from transformed K5+/K19+  (Table 3.2) or K5+/K19- mRas/mp53/wtEGFR cells (Table 
3.3). Increased collagen expression has been previously shown to be associated with 
EMT like behavior of the tumor cell (Wei et al. 2015). PRRX1, an important mediator of 
EMT and metastasis (Ocana et al. 2012) in tumor cell was also found to be highly 
expressed in this combination as compared to tumors from K5+/K19- 
mRas/mp53/wtEGFR (Table 3.2), further correlated the up-regulated EMT status of 
K5+/K19- mRas/mp53/wtErbB2 tumors. Basal cyto-keratin K6 was also found to be 
differentially downregulated in these EMT like K5+/K19- mRas/mp53/wtErbB2 tumors as 
compared to K5+/K19- mRas/mp53/wtEGFR or tumors from transformed K5+/19+ cells 
with either combination. 
Extracellular matrix proteins- LUM and DEC were observed to be highly 
expressed in K5+/K19- mRas/mp53/wtEGFR tumors (Table 3.4). LGR5 marker of 
intestinal stem cells was found to be highly expressed in K5+/K19+ 
mRas/mp53/wtErbB2 tumors (Table 3.5). When we compared primary with the 
metastatic tumor from K5+/K19+ mRas/mp53/wtEGFR combination, we found that 
amino acid transporter protein SLC6A14 was highly up regulated (Table 3.6). 
Additionally, markers associated with EMT and metastasis in tumors from breast cancer 
patients including- POSTN, GREM1, PTGS2 (Grigoriadis et al., 2006; Malanchi et 
al.,2012; Minn et al., 2005)   were upregulated in primary tumors from K5+/K19+ 
mRas/mp53/wtEGFR combination (Table 3.6). We confirmed the expression of most 
highly expressed genes in metastatic tumors - SLC6A14, OLFM4, STEAP2 and RERG 
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in three different mice derived paired primary and metastatic tumors and found SLC6A14 
to be consistently high in metastasis as compared to primary tumors, suggesting an 
important role of this protein at metastatic sites (Figure 3.2). Similarly, we also tested the 
expression of genes differentially expressed in primary tumors- GREM1, POSTN, 
PTGS2 and SLC2A3. Out of these, POSTN and PTGS2 were found to be consistently 
increased in two independent mice primary tumors (Figure. 3.3).  
 















Figure 3.1: Different combination tested for gene expression analysis of primary 
or metastatic tumors 
 
 
    
Figure 3.1: Different combination tested for gene expression analysis of primary 
or metastatic tumors. Microarray derived gene expression changes in primary tumors 
from K5+/K19- mp53/mRas/wtErbB2, K5+/K19+ mp53/mRas/wtErbB2, K5+/K19-
mp53/mRas/wtEGFR or K5+/K19+ mp53/mRas/wtEGFR and metastatic tumor from 
K5+/K19+ mp53/mRas/wtEGFR combination were compared with each other in different 







Table 3.2: Differentially expessed genes in K5+/K19- mp53/mRas/wtErbB2 tumors 







Table 3.3: Differentially expessed genes in K5+/K19- mp53/mRas/wtErbB2 tumors 









Table 3.4: Differentially expessed genes in K5+/K19- mp53/mRas/wtEGFR tumors 









Table 3.5: Differentially expessed genes in K5+/K19+ mp53/mRas/wtErbB2 tumors 









Table 3.6: Differentially expessed genes in metastatic tumors as compared to 









Figure 3.2: mRNA expression analysis for genes up-regulated in metastatic 
tumors from K5+/K19+ mp53/mRas/wtEGFR combination 
 
            
                             
 
Figure 3.2: mRNA expression analysis for genes up-regulated in metastatic 
tumors from K5+/K19+ mp53/mRas/wtEGFR combination. mRNA extracted from 3 
independent mice paired primary and metastatic tumors (A, B and C) was analyzed by 
real time PCR for expression of SLC6A14, OLFM4, STEAP4 and RERG. Each sample 








Figure 3.3: mRNA expression analysis for genes up-regulated in primary tumors 
from K5+/K19+ mp53/mRas/wtEGFR combination 
 
 
                                         
                                 
 
Figure 3.3: mRNA expression analysis for genes up-regulated in primary tumors 
from K5+/K19+ mp53/mRas/wtEGFR combination. mRNA extracted from 3 
independent mice paired primary and metastatic tumors (A, B and C) was analyzed by 
real time PCR for expression of GREM1, PTGS2, POSTN and SLC2A3. Each sample 








Analysis of EMT and metastasis gene signature in tumors from transformed 
K5+/K19- or K5+/K19+  
In order to better understand the differences in incidence and latency for primary 
and metastatic tumors from different groups i.e. K5+/K19- mp53/mRas/wtErbB2, 
K5+/K19+ mp53/mRas/wtErbB2, K5+/K19- mp53/mRas/wtEGFR or K5+/K19+ 
mp53/mRas/wtEGFR, we analyzed the mRNA expression of various EMT and 
metastasis related genes in these tumors (Minn et al., 2005; Soundararajan et al. 2015). 
Fold change in expression was derived by comparing different primary or metastatic 
tumors with each other as shown in Table 3.7. We observed, that tumors formed by 
transformed K5+/K19- cell type overall had a higher expression of EMT related genes 
including- ZEB1, ZEB2, SNAI2, PRRX1, TWIST1, VIM and loss of CDH1 or E-Cadherin 
(Table 3.7) as compared to those from transformed K5+K19+ tumors. These results are 
in concordance with and confirm the EMT phenotype observed for tumors from 
transformed K5+/K19- as previously shown in chapter 2 (Figure 2.6 and 2.7). 
Interestingly, tumors from K5+/K19- over-expressing oncogene combination expressing 
mp53/mRas/wtErbB2 had a higher EMT gene signatures as compared to those from 
K5+/K19- over-expressing mRas/mp53/wtEGFR. Correspondingly, the lung metastatic 
tumor derived from K5+K19+ mRas/mp53/wtEGFR had an up-regulated epithelial gene 
expression including CDH1 and down regulated EMT gene signatures such as CDH2, 
SNAI2, TWIST1, TWIST2, ZEB1 or ZEB2 (Table 3.7). Immunostaining of the lung 
metastatic tumor also showed a high expression of luminal marker MUC1 (Figure 3.4A) 
and α-SMAneg/vimentinlow or E-Cadherinpositive/ vimentinlow phenotype (Figure 3.4B, 3.4C), 
confirming their epithelial phenotype. 
Metastasis signature genes- CXCL1, MMP1, PTGS2, that are previously shown 
to be up-regulated in primary tumors in patients having metastasis were included for the 
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analysis (Minn et al., 2005). We observed an up-regulated expression of metastasis 
genes PTGS2 and MMP-1 in the primary tumors from K5 + K19+ mRas/mp53/wtEGFR 
combination as compared to its corresponding metastatic tumor (Table 3.7). As 
previously observed, primary tumor from K5+K19+ mRas/mp53/wtEGFR combination 
had high expression of PTGS2 (Table 3.6) as compared all other primary tumors (Table 

















Table 3.7: Analysis of EMT and metastasis gene signature in tumors from 








Figure 3.4: Epithelial phenotype of lung metastatic tumor from K5+/K19+ 
mp53/mRas/wtEGFR combination. 
 
                                      
       
       
Figure 3.4: Epithelial phenotype of lung metastatic tumor from K5+/K19+ 
mp53/mRas/wtEGFR combination. Immunohistochemical staining of lung tumor 
sections from K5+/K19+ mp53/mRas/wtEGFR. A) Representative image of tumor 
section stained with anti-MUC1 antibody. Representative image (magnification 20X)of  
tumors double immunostained with B) anti-αSMA (green) and anti-vimentin (red) show 
presence of (α-SMAnegative/vimentinlow) area within metastatic tumor. C) Same tumor 
sections double immunostained with E-Cadherin (green) and vimentin (red) show 







Shared and unique networks and canonical pathways in tumors formed from 
transformed K5+/K19- or K5+/K19+  
In order to identify networks and canonical pathways that were altered in these 
tumors, we performed bioinformatic analysis using IPA (Kramer et al. 2013), on the 
genes that were differentially expressed in various combinations (Table 3.2-3.6).  From 
IPA, we identified cancer (range of molecules involved: 61-77), organismal injury and 
abnormalities (61-77) and reproductive system disease (42-58), as the topmost disease 
and biological functions associated with each combination. Cellular movement (26-46), 
cell-to-cell signaling and interaction (18-43), cell death and survival (29-46) were the top 
molecular and cellular function identified in various combinations. Besides these, each 
combination had a unique function associated with them (Table 3.8) that may be 
resulting from the differential effect of either the cell type or the oncogene in different 
groups. Top regulator effect network as analyzed by IPA, show association of -
“chemotaxis of neutrophils” with tumors from K5+/K19- over-expressing 
mp53/mRas/wtErbB2 or “activation of neutrophils” with tumors from K5+/K19+ over-
expressing mp53/mRas/wtErbB2 (Table 3.9). Activation of osteoclast and remodeling of 
bone was the top regulator effect network observed, when primary tumor from K5+/K19+ 
mp53/mRas/wtEGFR was compared with its respective metastatic tumor (Table 3.9).  
Atherosclerosis signaling, hepatic fibrosis/hepatic stellate cell activation, 
agranulocyte adhesion and diapedesis, role of IL-17A in psoriasis, cell cycle: G2/M DNA 
damage checkpoint regulation and HMGB1 signaling were the most common top 
canonical pathways associated with each combination. Tumors from K5+/K19- over-
expressing mp53/mRas/wtErbB2 oncogene combination show inhibition of matrix 
metalloproteinase (MMPs) and glutathione redox reaction as the associated canonical 
pathway when compared with tumors from K5+/K19+ over-expressing 
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mp53/mRas/wtErbB2 (Table 3.10), suggesting a likely cell type effect. Tumors from 
K5+/K19- over-expressing mp53/mRas/wtEGFR show altered DNA damage induced 14-
3-3 signaling and those from K5+/K19+ over-expressing mp53/mRas/wtEGFR show 
differential regulation of cytokine production and role of osteoclast, osteoblast and 
chondrocytes in rheumatoid arthritis as the associated canonical pathway (Table 3.10).   
Cellular movement, hematological system development and function, immune cell 
trafficking, dermatological diseases and conditions, cancer and organismal injury and 
abnormalities were the topmost associated networks associated with tumors from 
different combination (Figure 3.5-3.10). The networks associated with tumor from 
K5+/K19- over-expressing mp53/mRas/wtErbB2 oncogene combination were 
characterized by increase in expression of collagens including COL1A1, COL3A1 and 
COL15A1 and low expression of MMPs, S100 proteins -S100A8, S100A9, S100P and 
cyto-keratins 6 and 15 (Figure 3.5, 3.6 and 3.7). Comparative analysis of tumors from 
K5+/K19- or K5+/K19+ over-expressing mp53/mRas/wtEGFR, showed hair and skin 
development and function as the top associated network, that it was characterized by an 
upregulated expression of extracellular matrix proteins- COL, LUM, DEC, EMT marker- 
ZEB1 and Wnt pathway (Wnt 5A ↑, Wnt inhibitor DKK ↓) (Figure 3.8) . Cellular 
movement, skeletal and muscular system development and function, cell-to-cell 
signaling and interaction was the top most associated network in tumor from K5+/K19+ 
over-expressing mp53/mRas/wtErbB2 (Figure 3.9), while comparison of primary and 
metastatic tumors from K5+/K19+ over-expressing mp53/mRas/wtEGFR showed 

















































Figure 3.5: Top associated network (I) for K5+/K19- mRas/mp53/wtErbB2 versus 
K5+/K19+ mRas/mp53/wtErbB2 combination. 
  
Figure 3.5: Top associated network (I) for K5+/K19- mRas/mp53/wtErbB2 versus 
K5+/K19+ mRas/mp53/wtErbB2 combination. Cellular Movement, Hematological 
System Development and Function, Immune Cell Trafficking were the associated 







Figure 3.6: Top associated network (II) for K5+/K19- mRas/mp53/wtErbB2 versus 
K5+/K19+ mRas/mp53/wtErbB2 combination. 
 
Figure 3.6: Top associated network (II) for K5+/K19- mRas/mp53/wtErbB2 versus 
K5+/K19+ mRas/mp53/wtErbB2 combination. Dermatological Diseases and 








Figure 3.7: Top associated network for K5+/K19- mRas/mp53/wtErbB2 versus 
K5+/K19- mRas/mp53/wtEGFR combination. 
 
Figure 3.7: Top associated network for K5+/K19- mRas/mp53/wtErbB2 versus 
K5+/K19- mRas/mp53/wtEGFR combination. Dermatological Diseases and 









Figure 3.8: Top associated network for K5+/K19- mRas/mp53/wtEGFR versus 
K5+/K19+ mRas/mp53/wtEGFR combination. 
 
Figure 3.8: Top associated network for K5+/K19- mRas/mp53/wtEGFR versus 
K5+/K19+ mRas/mp53/wtEGFR combination. Dermatological Diseases and 
Conditions, Hair and Skin Development and Function, Cancer were the associated 









Figure 3.9: Top associated network for K5+/K19+ mRas/mp53/wtErbB2 versus 
K5+/K19+ mRas/mp53/wtEGFR combination. 
 
Figure 3.9: Top associated network for K5+/K19+ mRas/mp53/wtErbB2 versus 
K5+/K19+ mRas/mp53/wtEGFR combination. Cellular Movement, Skeletal and 
Muscular System Development and Function, Cell-To-Cell Signaling and Interaction 








Figure 3.10: Top associated network for metastatic versus primary tumors from 
K5+/K19+ mRas/mp53/wtEGFR combination. 
 
 
Figure 3.10: Top associated network for metastatic versus primary tumors from 
K5+/K19+ mRas/mp53/wtEGFR combination. Connective Tissue Disorders, 
Dermatological Diseases and Conditions, Developmental Disorder were the associated 








The process of breast cancer progression is governed by various gene 
expression changes occurring within the cells of primary tumor as well as by alterations 
in the tumor microenvironment. Tumor cells undergo genetic and epigenetic 
modifications in order to acquire properties that allow extravasation from the primary 
tumor site, survival in the circulation and finally colonization at the secondary metastatic 
site. In order to do so, cells undergo the process of EMT and MET so as to metastasize 
to different locations in the body (Del Pozo Martin et al.,2015; Thiery et al., 2009).  
Patients with invasive breast cancer have metastatic tumors mostly in bones, lungs and 
brain. Gene expression profiling studies have identified gene signatures that predict the 
progression of disease and metastasis in patients (Minn et al., 2005; van 't Veer et al., 
2002). However, the pathways that govern the pathogenesis of disease and its eventual 
progression to various secondary locations are still under investigation. Here, we used 
our transformed K5+/K19- or K5+/K19+ cells derived tumor models (described in chapter 
2), to study the gene changes occurring during the process of disease progression. We 
found that tumors from K5+/K19- cells over-expressing mRas/mp53/wtErbB2 
combination, despite of having a shorter primary tumor latency had a higher latency and 
lower incidence  for metastasis (Table2.1, 2.2-Chapter 2). We also observed that tumors 
from transformed K5+/K19+ cells overall had a higher metastasis efficiency than those 
transformed K5+/K19- cells. Most breast tumors have a high K19 expression (Bartek et 
al., 1985). Notably, the CTCs in patients with a relapsing or metastasis disease are 
CK19 positive (Giuliano et al., 2014; Xenidis et al., 2009). In this chapter, we analyzed 
the mRNA expression changes within different tumors (Figure 3.1) in order to identify the 
factors that might govern disease pathogenesis within different combinations. We 
observed that tumors formed by transformed K5+/K19- cellular precursors, mostly had 
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an upregulated EMT gene expression in comparison to those from tumors transformed 
K5+/K19- cells (Table 3.1, Table 3.6). Specifically, tumors from K5+/K19- cells over-
expressing mRas/mp53/wtErbB2 were characterized by increased expression of 
collagens including COL15A and COL3A, transcription factors – ZEB1, ZEB2, SNAI2 
TWIST1, PRRX1 and decreased basal keratin expression than K5+/K19- cells over-
expressing mRas/mp53/wtEGFR (Table 3.2, 3.3, 3.7), suggesting likely effect of 
oncogene ErbB2 in inducing more EMT characteristics in comparison to EGFR.  
Although, the tumor from K5+/K19- mRas/mp53/wtErbB2 combination had an up 
regulated EMT gene signature, they do not show a good correlation with metastasis 
formation efficiency in-vivo (Table 3, chapter 2). Contrary to the known literature, that 
higher EMT in tumor would indicate a higher metastasis we found that overall tumors 
with basal like expression in addition to EMT markers (K5+/K19+ mRas/mp53/wtEGFR 
combination) had a higher metastasis forming efficiency. Our results are in concordance 
with the recent report that shows that basal stem cell signature in addition to EMT is 
associated with higher metastasis burden (Lawson et al. 2015). Another study done by 
Soundarajan et al, also showed that high expression EMT gene signatures (PRRX1, 
TWIST1, SNAI2, VIM) induced during embryonic development, does not correlates 
significantly with metastatic or recurrent disease (Soundararajan et al. 2015), suggesting 
that mere upregulation EMT genes may not be the only determinant of tumor 
dissemination and metastasis in breast cancer. Inhibition of matrix metalloproteinase 
(MMPs) pathway (as analyzed by IPA) in tumors from K5+/K19- over-expressing 
mp53/mRas/wtErbB2 oncogene combination also provide likely explanation for the lower 
metastasis formation from this combination (Table 3.10). 
Homeobox factor 1 (PRRX1), a transcription factor that induces EMT, was highly 
elevated in tumors from transformed K5+/K19- (Table 3.7). PRRX1 is shown to play an 
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important role in EMT and metastasis, and loss of PRRX1 is required by cancer cells to 
colonize at secondary locations (Ocana et al. 2012). In accordance with these results, 
we found a similar correlation between high PRRX1 in primary tumor and lowering of its 
expression in metastatic tumors in K5+/K19+ mRas/mp53/wtEGFR combination (Table 
3.7). Upon analysis of mRNA expression, we found that expression of PRRX1 was lower 
in the parental K5+/K19- or K5+/K19+ untransformed cells (Zhao et al. 2010). However, 
we found an induction of PRRX1 expression upon transformation of these cells by 
mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR oncogene combination, more so for 
K5+/K19- over-expressing mRas/mp53/wtErbB2.  These results, therefore suggest that 
K5+/K19- cells have a higher susceptibility to undergo EMT by upregulating PRRX1 
expression upon transformation.  
Furthermore, we found that tumor from mRas/mp53/wtEGFR transformed 
K5+/K19+ cells, overall had a lower upregulation of EMT gene signature in comparison 
to those from transformed  K5+/K19- cells, but they expressed more metastasis related 
gene signatures (Table 3.7). Upregulated expression of PTGS2, MMP1, CXCL1 has 
been shown to be associated with breast tumorigenicity and lung mutagenicity (Minn et 
al., 2005).  We found that PTGS2 was highly expressed in primary tumors from 
K5+/K19+ mRas/mp53/wtEGFR combination, signifying that our data is in accordance 
with known literature. Bioinformatic analysis using IPA also validate the nature of these 
tumor models as we observed, cancer and reproductive system disease as the top 
disease associated with each combination.  
Lastly, we found amino acid transporter SLC6A14, as the most highly expressed 
gene in metastatic tumors in comparison to primary tumor from K5+/K19+ 
mRas/mp53/wtEGFR combination, emphasizing its importance in metastatic disease 
(Table 3.6). SLC6A14, is important for tumor development and knockout mouse fail to 
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form spontaneous tumors (Babu et al. 2015). Analysis of three independent paired 
primary and metastatic tumors from different mice consistently showed an up regulated 
SLC6A14 expression (Figure 3.2). It therefore suggests, that amino acid metabolism 
may be an important process required for colonization at new locations and it can serve 
as probable therapeutic target to cure metastatic diseases (Karunakaran et al.,2011; 
McCracken and Edinger).   
Our results although based on microarray data from single tumor from each 
combination, showed a good association with the expression of known markers for 
metastatic disease and explain the differences in relative primary tumor and metastasis 
latency and incidence which we reported earlier. Furthermore, we also validated these 
results in tumors derived from different mice (Figure 3.2, 3.3). In addition, we also 
identified certain genes that are characteristic of metastatic tumors and could be 
potential therapeutic targets to cure high grade tumors. In conclusion, we found that 
tumors from transformed K5+/19- or K5+/19+ cells overall have different susceptibility for 
metastasis formation due to differential gene expression associated with each primary 
tumor and which in turn also governs the tumor characteristics and EMT. Further 
exploration of pathways associated with the genes identified in the current analysis 
would provide an important insight into the process of primary tumor dissemination and 
metastasis in human patients as well as provide important therapeutic target to tackle 














Differential EMT induction in K5+/K19- and K5+/K19+ stem/progenitors upon 
oncogenic transformation with mRas/mp53/mPI3K  














Breast cancer is a heterogeneous disease and is classified into different 
subtypes, namely- Luminal-like, ErbB2 over-expressing, Basal-like and Claudin-low 
(Perou et al., 2000; Prat et al., 2010; Sorlie et al., 2001). Different subtypes have 
characteristic gene expression changes, that involve over-expression, hyper or hypo 
DNA methylation or mutations in key oncogenes or tumor suppressor (TCGA 2012, 
Banerji et al., 2012; Sorlie et al., 2001; Stephens et al. 2012). The nature of cell type that 
gets transformed is an important determinant for development of different breast tumor 
types (Bhagirath et al., 2015 ; Ince et al., 2007; Johnson et al.,2014; Keller et al., 2012; 
Melchor et al. 2014). More recently, we and others have shown that the transforming 
oncogenes also play an important role in determining the pathogenesis and progression 
of disease (Bhagirath et al., 2015; Melchor et al. 2014). As described previously in 
Chapter 2, we investigated the role of oncogene combinations mRas/mp53/wtErbB2 or 
mRas/mp53/wtEGFR in determining breast tumor type from mammary stem/progenitor 
cell lines designated as K5+/K19- and K5+/K19+, by over-expressing these oncogene 
combinations. Prevalence of these oncogenes (ErbB2, EGFR) in different BC subtypes 
(luminal-like, ErbB2 over-expressing or basal-like) and their association with poor 
survival outcome in patients suggest that these oncogenes may play an important role in 
BC pathogenesis. Indeed, we found an important relationship between the oncogene 
that is over-expressed, with the cell type in which it is present and their combinatorial 
effect in governing the tumor phenotype as well as primary tumor and metastasis 
latencies. K5+/K19- cells over-expressing ErbB2 in combination with mRas and mp53 
generated primary tumors with shorter latency in comparison to K5+/K19- cells over-
expressing mRas/mp5/wtEGFR. Although, the latency for primary tumor formation was 
much higher for K5+/K19- over-expressing mRas/mp5/wtEGFR, these cells had a similar 
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latency for developing lung metastasis as that of K5+/K19- cells with 
mRas/mp5/wtErbB2. Another important observation was that, the nature of cell type also 
determined the metastasis latency and incidence. K5+/K19+ cells overall had a higher 
rate of developing metastasis than K5+/K19- transformed cells, suggesting an increased 
susceptibility of K5+/K19+ precursors for metastasis. Given, these differential effects of 
oncogenes and cell type on pathogenesis of breast tumors, in the current study we 
investigated the effect of over-expression of oncogene combination mRas/mp53 along 
with mutant PI3K on K5+/K19- and K5+/K19+ cells. PI3K is the most commonly mutated 
oncogene in luminal like breast tumors (TCGA 2012). It has been previously shown that 
combination of Ras and PI3K can efficiently transform hMECS in vitro (Oda et al., 2008; 
Wang et al. 2013)  and more recently it has been demonstrated that induction of PI3K 
mutation in different cell lineages affects the tumor phenotype (Van Keymeulen et al. 
2015).  
We observed that over-expression of oncogene combination mRas/mp53/mPI3K 
drives complete EMT in K5+/K19- cells whereas a mixed epithelial and EMT phenotype 
in K5+/K19+ cells. The tumors formed in-vivo by same oncogene combination gave rise 
to metaplastic carcinomas from transformed K5+/K19- and mixture of metaplastic and  
adenocarcinomas from transformed K5+/K19+, with an overall higher EMT 
characteristics in both the tumors. This study and our previous findings strongly suggest 
an increased susceptibility of K5+/K19- precursors to undergo EMT upon transformation 






4.2 MATERIALS AND METHODS 
Cell lines and retroviral/lentiviral infection  
Mutant p53R249S in pLENTI-6 (purchased from Addgene) along with Invitrogen 
packaging vector (ViraPowerTM Lentiviral Packaging MIX) were transfected into 293FT 
packaging cells.  Lentiviral supernatants were collected after overnight incubation in 
fresh DMEM media. TSA54 packaging cells were transfected with retroviral constructs, 
mutant H-Ras Q61L in pBABE-hygro, mPI3KH1047 in pMSCV-puro vector, together with 
PIK plasmid for packaging, and viral supernatants were collected  (as mentioned above 
for lentiviral). K5+/K5+/K19- and K5+/K19+ stem/progenitor cell lines (Zhao et al. 2010) 
were infected with viral supernatants to generate cell lines with different gene 
combinations followed by their selection in DFCI-1 medium (Band and Sager, 1989; 
Band et al., 1990) containing hygromycin (15ul/ml) (for mutant H-Ras), blasticidine 
(15ul/ml) (for mutant p53), puromycin (0.5ul/ml) (for mPI3K). 
 
Antibodies  
The following antibodies were used for western blotting, immunofluorescence, 
flow-cytometry and IHC: mouse anti-human p53 (DO-1) (sc-126), mouse anti-human α-
smooth muscle actin (SMA) (sc-32251), mouse anti-human vimentin (sc-6260) were 
from Santa Cruz Biotechnology. Mouse anti-human Ras (610001), mouse anti-human 
MUC1 (550486), rat anti-human CD49f (555734), FITC conjugated anti-CD24 (555427), 
PE-conjugated anti-CD44 (555479) and Alexa-488 conjugated E-Cadherin (560061) 
were from BD Bioscience. Rabbit anti-human vimentin (clone SP20, RM-9120-S0) was 




Anchorage-independence growth assay 
40,000 cells suspended in DFCI-1 medium containing 0.3% agarose were 
seeded in the top layer of each well of 6-well plates containing 0.6% agarose as a 
bottom layer. Each cell line was plated in triplicates. Colonies (>60 cells) were counted 
after 3 weeks after crystal violet staining.  
 
Flow cytometry analysis   
1 million cells were incubated with FITC conjugated anti-CD24 and PE-
conjugated anti-CD44 at 4oC for 45 min. Following incubation, the cells were washed 
three times with washing buffer (phosphate buffer saline with 0.2% fetal bovine serum) 
and were subjected to fluorescence-activated cell sorter (FACS) analysis. 
 
Migration and invasion assay 
20,000 cells were plated in trans-well chambers (BD-for migration, BD-for 
invasion) and incubated at 37oC for 13Hrs. or 23Hrs. Migration or invasion of plated cells 
was stopped at respective time periods. Cells on upper chamber were cleaned using 
cotton swab, while the cells on the bottom of the chamber were fixed with HEMA fixative 
(#122-911A), followed by staining with HEMA solution I (#122-911B) and HEMA solution 






In vitro matrigel polarity assay  
Protocol used for matrigel assay has been described previously (Zhao et al., 
2011; Zhao et al. 2012). Briefly, 1000 cells suspended in DFCI-1 medium containing 2% 
matrigel were plated on glass coverslips with 100% reconstituted basement membrane 
(matrigel from BD Biosciences in 24 well plate.  After 12 days (alternate day feeding) 
cells were stained with FITC conjugated anti-CD227 (MUC1) and PE-Cy5 conjugated 
anti- CD49f and analyzed under Zeiss 510 confocal microscope (UNMC facility).  
 
Xenograft transplantation assays for primary tumor formation 
 6-8 weeks old immunodeficient NOD-SCID gamma (NSG) mice (purchased from 
Jackson laboratories) were orthotopically injected with 1 million cells (not tagged with 
GFP-luciferase) in DFCI-1 medium mixed with matrigel in 1:1 proportion (Ince et al., 
2007) in the fourth and ninth (contralateral) mammary glands. 4 mice were used for each 
combination. Tumor formation was assessed by palpation in the area of injection every 
week until 6 months. After six months, mice with or without tumors were sacrificed by 
CO2 inhalation followed by cervical dislocation. Tumors were excised, fixed with 10% 
neutral buffered formalin and processed to prepare paraffin-embedded tumor blocks that 
were then sectioned for IHC. 
 
Immunohistochemistry 
Tumor tissues were fixed in 10% Neutral buffered Formalin (NBF) and processed 
into paraffin blocks. 4 μm sections were cut and stained with indicated antibodies. The 
standard staining procedure was performed using DAKO kit as per the manufacturer’s 
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protocol (# K4007) and as described (Zhao et al. 2012). For IHC staining, tissue sections 
were incubated with primary antibodies (anti-K5, anti-MUC1, anti-vimentin or anti-α-
SMA) in a hydrated chamber, followed by incubation with HRP-tagged secondary IgG 
against the primary antibodies and DAB solution and subsequently processed for 
nuclear staining with hematoxylin and mounting of tissues. For double-
immunofluorescence staining tumor sections were processed similarly and blocked with 
10% goat serum for 1 hr. These were then stained with rabbit anti-vimentin, alexa 488 
conjugated anti-E-cadherin or mouse anti- α-SMA antibodies. Goat anti-rabbit alexa 594 
and goat anti-mouse alexa 488 conjugated secondary antibodies (Invitrogen) were used 
for staining. The sections were mounted with anti-fade mounting media. Images were 
taken with fluorescence microscope (Zeiss axioplan 2 imaging microscope). 
 
Isolation and culture of primary tumor derived cells 
Xenograft tumors were excised from NSG mice and minced with sterilized 
scalpel in clean P-60 petri dishes. Minced tumors were cultured in either alpha-MEM or 
DFCI1 medium for 1-2 weeks, following which the cells were trypsinized. Isolated cells 
were then subjected to antibiotic (blasticidine, hygromycin and puromycin) selection to 









Over-expression of mRas/mp53/mPI3K leads to oncogenic transformation of 
K5+/K19- and K5+/K19+ cells 
Oncogene combination mRas/mp53/mPI3K was ectopically over-expressed in 
K5+/K19- and K5+/K19+ cell lines and stable cells lines were generated using antibiotic 
selection. Protein expression of over-expressed genes was analyzed by western blotting 
(Figure 4.1A). To test if over-expression of mRas/mp53/mPI3K transforms the two cell 
types we performed in-vitro anchorage independence assay. Both, K5+/K19- and 
K5+/K19+ cells upon over-expression of mRas/mp53/mPI3K give rise to colonies in 
0.3% agar (Figure 4.1B), signifying a complete in-vitro transformation. This assay is still 













Figure 4.1: In-vitro transformation of K5+/K19- and K5+/K19+ cells by 
mRas/mp53/mPI3K 
                      
 






Figure 4.1: In-vitro transformation of K5+/K19- and K5+/K19+ cells by 
mRas/mp53/mPI3K. A). K5+/K19- or K5+/K19+ cell lines over-expressing vector or 
mRas/mp53/mPI3K oncogene combination were analyzed by Western Blotting. β-Actin 
was used as loading control. B). Representative images (magnification 40X) of colonies 
from K5+/K19- and K5+/K19+ cells with vector or mRas/mp53/mPI3K oncogene 


















Oncogenic transformation with mRas/mp53/mPI3K oncogene combination leads 
to complete and partial EMT in K5+/K19- and K5+/K19+ cells respectively. 
We further observed that in addition to in-vitro transformation, over-expression of 
mRas/mp53/mPI3K led to generation of complete EMT in K5+/K19- cells and mixed 
EMT and epithelial morphology in K5+/K19+ cells in-vitro in culture. To further confirm 
this differential effect on K19- and K19+ cellular precursors, we over-expressed 
mRas/mp53/mPI3K in different clones derived from K5+/K19- and K5+/K19+ cells. Both 
the clones displayed differences in morphology as expected (Figure 4.2A). This is in 
contrast with the previously observed transformations with oncogene combinations 
mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR, where complete EMT was only observed 
in-vivo in tumors from K5+/K19- with ErbB2 combination. The transformed K5+/K19- 
cells with mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR however had an epithelial 
morphology in-vitro. Thus, suggesting that PI3K is more potent EMT inducer than ErbB2 
or EGFR and it is drives K5+/K19- cellular precursors to complete phenotypic EMT in-
vitro. Figure 4.2A shows phenotypic differences in morphology of K19- clone 62 and 
K19+ clone 21. We also assessed expression of different EMT markers (E-Cadherin, 
vimentin) in mRas/mp53/mPI3K transformed K5+/K19- and K5+/K19+ cell lines. As 
expected transformed cells showed a decrease in E-Cadherin and increase in vimentin 
expression (Figure 4.2B) 
We assessed expression of cell surface markers CD44 and CD24 in 
mRas/mp53/mPI3K transformed K5+/K19- and K5+/K19+ cells, to identify 
CD44high/CD24low cell population within these cells. CD44high/CD24low is a marker for 
tumor-initiating cells (Al-Hajj et al., 2003) and its expression is associated with EMT like 
Claudin-low tumors (Prat et al. 2010). We observed that K5+/K19- transformed cells that 
had undergone complete EMT in-vitro showed a significant shift towards 
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CD44high/CD24low phenotype as compared to transformed K5+/K19+ cells (Figure 4.3).  
These results are in accordance with the respective EMT morphologies observed for the 
two transformed cell lines and K5+/K19- transformed cells as expected shows higher 
CD44high/CD24low population as compared to mixed EMT and epithelial K5+/K19+ 
transformed cells. 
We then determined the functional effects of mRas/mp53/mPI3K over-expression 
in K5+/K19- and K5+/K19+ cells. For that, we first assessed the migration and invasion 
abilities of the transformed cell lines in-vitro. We observed that both the 
mRas/mp53/mPI3K transformed K5+/K19- and K5+/K19+ cells had an increased 
migration and invasion ability as compared to vector cells (Figure 4.4A, 4.4B). PI3K 
oncogene has been associated with increased EMT like characteristics and is expected 
to increase the migratory and invasive capacity of cells. Thus, over-expression of 
mRas/mp53/mPI3K in K5+/K19- or K5+/K19+ affects cellular pathways of both the cell 
types towards increased motility and invasion. However, we did not observed any 
difference in the invasion or migration abilities between transformed K5+/K19- or 
K5+/K19+, despite the differences in extent of EMT in the two cell lines.  
Next, we assessed the ability of mRas/mp53/mPI3K transformed K5+/K19- or 
K5+/K19+ cells to form polarized acinar structure in matrigel. We observed that EMT like 
transformed K5+/K19- cells lose their ability to form polarized acini and give rise to 
branched invasive structures with a low CD49f staining (Figure 4.5A). K5+/K19+ cells 
however, still maintain their ability to form acini upon transformation and form branched 
structure and rounded acini in matrigel (Figure 4.5B) as opposed to transformed 
K5+/K19- cells, suggesting a differential effect of mRas/mp53/mPI3K oncogene 
combination on K5+/K19- and K5+/K19+ cells.  
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Figure 4.2: Differential EMT in mRas/mp53/mPI3K transformed K5+/K19- and 
K5+/K19+ cell lines. 
 
                                  
 
                           
Figure 4.2: Differential EMT in mRas/mp53/mPI3K transformed K5+/K19- and 
K5+/K19+ cell lines. Phase contrast images showing differences in EMT phenotype in 
transformed K5+/K19- (clone 62) or K5+/K19+ (clone 21) cells (magnification 10X). B) 
Parental or transformed K5+/K19- or K5+/K19+ cells were analyzed by western blotting for 






Figure 4.3: Expression of CD44high/CD24low population in mRas/mp53/mPI3K 
transformed K5+/K19- and K5+/K19+ cells 
 
           
 
Figure 4.3: Expression of CD44high/CD24low population in mRas/mp53/mPI3K 
transformed K5+/K19- and K5+/K19+ cells. Vector or transformed K5+/K19- or 
K5+/K19+ cells were stained with stem cell markers CD44 and CD24 and analyzed by 
flow Cytometry. Dot plot analysis of cell population expressing CD44high/CD24low (gated-
upper left).  
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Figure 4.4: Migration and invasion abilities of mRas/mp53/mPI3K transformed 
K5+/K19- and K5+/K19+ cells 
            
                   
                     
                
Figure 4.4: Migration and invasion abilities of mRas/mp53/mPI3K transformed 
K5+/K19- and K5+/K19+ cells. Vector or transformed K5+/K19- or K5+/K19+ cells were 
plated in trans-well chambers. Migration or invasion of cells was stopped at 13 Hr. and 
23Hrs. respectively. Cells were stained and counted to assess migration (A) and 





Figure 4.5: In-vitro matrigel polarity assay for mRas/mp53/mPI3K transformed 
K5+/K19- and K5+/K19+ cells. 
 
                                         
 






Figure 4.5: In-vitro matrigel polarity assay for mRas/mp53/mPI3K transformed 
K5+/K19- and K5+/K19+ cells. (A) Representative phase contrast images of branched 
structure and acini formed by vector transformed K5+/K19- or K5+/K19+ cells. (B) Vector 
or transformed K5+/K19- or K5+/K19+ cells were grown in DFCI-1 (differentiation) medium 
in Matrigel. Acini or branched structures were stained with PE-Cy5 conjugated anti-


















Transformed K5+/K19- and K5+/K19+ cells give rise to spindle like metaplastic 
carcinomas and adenocarcinomas in-vivo 
To confirm if the transformation observed in-vitro as a result of 
mRas/mp53/mPI3K over-expression in K5+/K19- and K5+/K19+ cells is complete, we 
assessed the tumor formation ability of the tranformed cell lines. Vector or 
mRas/mp53/mPI3K over-expressing K5+/K19- and K5+/K19+ were injected 
orthotopicaly in mammary glands of NSG mice. The vector cells as expected did not 
show any tumor formation, while both the transformed cells gave rise to mammary 
tumors in mice. mRas/mp53/mPI3K transformed K5+/K19- EMT like cells were most 
potent in forming tumors and all the 4 mice formed primary tumors within 4 weeks of 
injection. While mRas/mp53/mPI3K transformed K5+/K19+ had a latency period slightly 
higher than transformed K5+/K19- cells and injected mice formed tumors by 6th week of 
injection. Thereby, suggesting that EMT phenotypes may play an important role in 
forming early primary tumors. 
While the tumors formed by transformed K5+/K19- cells had a spindle like 
morphology and resembled metaplastic carcinomas of breast, those from transformed 
K5+/K19+ resembled adenocarcinomas with spindle like metaplastic carcinoma 
componenent (Figure 4.6A). We assessed the phenotypes of tumors by evaluating the 
expression of different makers for EMT, epithelial or stem-like cells such as MUC1 or E-
Cadherin for epithelial, α-sma or vimentin for EMT and K5 or vimentin for stem or basal-
like cells. Immunohistochemical analysis of tumors from transformed K5+/K19- showed a 
concordance in terms of expression of EMT markers, with the morphological EMT that 
was observed in-vitro (Figure 4.6B, 4.7A, 4.7B). Transformed K5+/K19+ as expected 
had a mixed expression for EMT and epithelial markers (Figure 4.6B, 4.7A, 4.7B), 
consistent with their morphology in-vitro. Overall, we observed increased EMT like 
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phenotype in tumors from mRas/mp53/mPI3K transformed K5+/K19- and K5+/K19+ 
cells, more so for transformed K5+/K19- cells.   
We then tested if the tumor cells isolated from primary tumors also maintain their 
EMT like morphology in-vitro upon culture. We observed, that tumor derived cells 
maintain the EMT or epithelial morphology as was observed in the injected parental cells 
(Figure 4.8), suggesting that oncogene combination mRas/mp53/mPI3K confers EMT 
like phenotype in K5+/K19- cells that is maintained by the cells. Morever, these EMT like 
cells derived from tumors formed by tranformed K5+/K19- cells had a drastically lower 
Pan-CK expression owing to the EMT induced as a result of mRas/mp53/mPI3K over-
expression. However, K5+/K19+ cells still retained expression of keratins after over-
expression, suggesting that K5+/K19- cells overall have a higher susceptibilty to 













Figure 4.6: mRas/mp53/mPI3K transformed K5+/K19- or K5+/K19+ cells give rise 
tumors with distinct EMT characteristics 
 











Figure 4.6: mRas/mp53/mPI3K transformed K5+/K19- or K5+/K19+ cells give rise 
tumors with distinct EMT characteristics. A) Representative images of H&E staining 
of tumor sections (magnification 20X upper panel, 40X lower panel) from K5+/K19- or 
K5+/K19+ cells over-expressing mRas/mp53/mPI3K. B) Images from different tumors at 
magnification 20X.  Immunohistochemical staining of tumor sections from transformed 
K5+/K19- or K5+/K19+ cells, with anti-CK5 (Basal/Stem), anti-vimentin (Basal/EMT), anti-
















Figure 4.7: mRas/mp53/mPI3K transformed K5+/K19- or K5+/K19+ cells give rise 














Figure 4.7: mRas/mp53/mPI3K transformed K5+/K19- or K5+/K19+ cells give rise 
tumors with distinct EMT characteristics. A) Representative images of  tumors from 
K5+/K19- orK5+/K19+ cells double immunostained with anti-αSMA (green) and anti-
vimentin (red) show presence of claudin-low (SMA+/vimentin+) areas within different 
tumors. B) Same tumor sections double immunostained with E-Cadherin (green) and 
vimentin (red) show presence of lowering of luminal like E-Cadherin+ staining. DAPI 

















Figure 4.8: mRas/mp53/mPI3K transformed K5+/K19- or K5+/K19+ tumor derived 




Figure 4.8: mRas/mp53/mPI3K transformed K5+/K19- or K5+/K19+ tumor derived 
cells maintain their EMT phenotypes. Tumors formed by transformed K5+/K19- or 
K5+/K19+ cells were excised and cultured to isolate primary tumor cells. Phase contrast 
images of parental transformed K5+/K19- or K5+/K19+ cells (upper panel) and tumor 
derived cells (lower panel) showing differences in EMT phenotype between the K5+/K19- 







Figure 4.9: Cyto-keratin expression in tumor derived cells from mRas/mp53/mPI3K 
transformed K5+/K19- or K5+/K19+ tumors. 
                   
                        
        
Figure 4.9: Cyto-keratin expression in tumor derived cells from mRas/mp53/mPI3K 
transformed K5+/K19- or K5+/K19+ tumors. Transformed A) K5+/K19- or B) K5+/K19+ 
parental or tumor derived cell lines were analyzed by Western Blotting. β-Actin was used 
as loading control. A- refers to cells cultured in alpha-MEM medium and D- refers to 





K5+/K19- cells have a pre-existing up-regulation of EMT like gene signatures as 
compared to K5+/K19+ cells. 
In order to understand underlying reason for phenotypic differences that occurred 
as a result of transformation by mRas/mp53/mPI3K over-expression, we analyzed the 
genes that were differentially expressed in the parental K5+/K19- or K5+/K19+ cells 
(Zhao et al. 2010). Table 4.1 and Table 4.2 shows list of genes that were up-regulated in 
K5+/K19- or K5+/K19+ cell types. Notably, K5+/K19- cells had an up-regulated 
expression of genes that are involved with activation of mesenchymal or desmoplastic 
stromal reaction in tumors. THBS2 was the most highly expressed gene in K5+/K19- 
cells. It has been shown to be involved in activation of fibroblasts in tumors (Del Pozo 
Martin et al.,2015; Kim et al. 2010). Collagen proteins- COL5A1 and COL5A2 that were 
found to be highly expressed in K5+/K19- cells, are also associated with EMT like 
phenotypes in tumors (Grigoriadis et al., 2006; Kiemer et al., 2001; Kim et al. 2010). 
However, we did not find any highly expressed transcription factor that could be 
responsible for inducing mesenchymal state in K5+/K19- cells or correlate with this high 
expression of EMT markers in the cells. Overall, these differences in the gene 
expression of EMT markers THBS2, COL5A1 or COL5A2 between K5+/K19- and 
K5+/K19+ cells, could be the likely reason for development or increased susceptibility of 
EMT from K5+/K19- than K5+/K19+ cells. In addition to comparing the gene expression 
changes with K5+/K19+, we also assessed the fold change with respect to K5-/K19- 
cells. K5-/K19- are myoepithelial progenitor cells that were generated previously from 
K5+/K19- or K5+/K19+ cells (Zhao et al. 2010) and have a phenotypically EMT like 
morphology in-vitro. We observed that, overall K5+/K19- cells had a closer expression 
correlation with the phenotypically EMT like myoepithelial progenitor cells than 
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K5+/K19+, suggesting that these cells have an existent gene expression profile that 





















Table 4.1: List of genes differentially up-regulated in K5+/K19- cells. 
 











Table 4.2: List of genes differentially up-regulated in K5+/K19+ cells. 
 












Heterogeneity in BC is widely prevalent and is responsible for failure of 
therapeutic response in patients. Several studies have focused on understanding the 
etiology of BC heterogeneity. Owing to several variable such as the microenvironment 
changes, accumulation of mutations, loss of differentiation, it becomes difficult to 
understand the underlying factors that initiate or possibly mediate progression of the 
disease. Using defined cellular precursors and by introducing different oncogenes we 
and others have observed that heterogeneity or subtypes in breast tumors is likely to be 
caused as an effect of both the nature of affected cell type as well as the 
oncogene(s)/tumor-suppresor altered in the cell (Bhagirath et al., 2015; Johnson et al., 
2014; Keller et al., 2012; Melchor et al. 2014). In the present study, we introduced 
mutant PI3K oncogene, that is widely mutated in luminal tumors, in addition to mutant 
Ras and mutant p53 in K5+/K19- or K5+/K19+ cells and we assessed the effect of the 
combination in driving pathogenesis from the two isogenic cell lines. The oncogene 
combination mRas/mp53/mPI3K was potent in driving both in-vitro transformation 
(Figure 4.1) and in-vivo tumor formation (Figure 4.6) as was expected based on earlier 
studies (Oda et al., 2008; Wang et al. 2013). As previously shown in Chapter 2, we 
observed differences in phenotypes of the tumors formed from mRas/mp53/mPI3K 
transformed K5+/K19- or K5+/K19+ cells, with transformed K5+/K19- giving rise to EMT 
like metaplastic carcinomas as compared to those from transformed K5+/K19+ cells 
(Figure 4.6, 4.7) and they maintained their in-vitro oncogene induced EMT like 
phenotype both in tumors as well as tumor derived cell lines (Figure 4.9). Additionally, 
we observed that mRas/mp53/mPI3K oncogene combination had a differential effect in 
driving EMT in K5+/K19- or K5+/K19+ cells.   
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These results are different from our previous observation with oncogene 
combinations mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR, where introduction of either 
of the two combinations did not induced any EMT morphology in-vitro in culture. Both, 
K5+/K19- or K5+/K19+ cells retained their epithelial phenotypes in-vitro upon over-
expression of these oncogenes combination. However, we did observed generation of 
EMT like metaplastic tumors from mRas/mp53/wtErbB2 transformed K5+/K19- cells. 
These results thereby suggest that mutant PI3K is more potent in inducing EMT than 
either ErbB2 or EGFR. In lieu of these observations, more recently it has been shown 
that mutant PI3K activates multipotency in different cell-types i.e. the luminal and basal 
cell lineages and generates heterogeneity of tumors based on the type of cell affected 
(Van Keymeulen et al. 2015). To understand the reason for variation in K5+/K19- and 
k19+ cells, we analyzed the genes that are differentially regulated in the parental 
K5+/K19- and K5+/K19+ cells.   
We identified that, overall K5+/K19- cells have an up-regulated gene signatures 
that correspond to EMT like phenotype as compared to K5+/K19+ cells. THBS2, was the 
most highly expressed gene in K5+/K19- and has been shown to be an important 
mediator of desmoplastic or stromal reaction in tumors. The secreted protein activates 
the myofibroblasts and facilitates in development of niches that favor metastasis and 
likely cause metaplastic phenotypes in tumors (Del Pozo Martin et al. 2015) . THBS2, 
COL5A1 and COL5A2, all of which were found to be highly expressed in  K5+/K19- cells, 
form the metastasis activating  or mesenchymal state inducing genes signature as 
shown previously (Kiemer et al., 2001; Kim et al. 2010). Thus up-regulation of such 
mesenchymal marker proteins in K5+/K19- cellular precursors, suggest that the intrinsic 
susceptibilities of K5+/K19- towards EMT phenotype could be governed by the existent 
gene expression within the parental cell type. It is however not necessary that induction 
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of EMT itself governs the progression of disease. Our previous study and work from 
others, has shown that mere up-regulation of EMT gene signatures does not correlate 
with metastatic disease (unpublished work, Ocana et al.,2012; Soundararajan et al. 
2015). EMT is important for migration of cells however, success of metastatic 
colonization relies on reversion of this phenotype (Del Pozo Martin et al. 2015) the 
capacity of which may vary from one cell to another. We observed that although 
transformed K5+/K19- had a higher tendency to undergo EMT, their ability to form 
metastatic tumors was lesser than transformed K5+/K19+ cells. Cellular precursor that 
are K19+, overall show a higher transformation as well as metastatic abilities (Bhagirath 
et al. 2015). This susceptibly of K19+ cells might be entirely governed by the nature of 
genes that is expressed by the cell type and may be further affected by the oncogene 
expressed by these cells that make metastasis faster or late (Bhagirath et al. 2015). 
Further investigation in to the gene expression changes in a K19+ cellular precursor, 
would warrant a better understanding of role of these cells in metastasis and provide for 
likely management of metastatic disease by therapeutically targeting these cell types.  
Our findings also highlight an important observation that, K19- cellular precursor 
as we know from literature do not form the major proportion of BC as compared to K19+ 
cells. These cells may have a lesser likelihood of getting transformed in-vivo and in 
event of transformation, these cells may have a lesser flexibility in modulating their EMT 
phenotypes as opposed to K19+ cells. Therefore, these cell types overall have lesser 
susceptibility for tumor or metastasis formation. In conclusion we observed that the 
intrinsic susceptibilities of different cell types govern the nature and characteristics of 

































Breast cancer is heterogeneous disease and is divided in to various subtypes. 
Gene expression analysis has allowed classification of breast tumors in following 
subtype: Luminal-like, ErbB2 over-expressing, basal-like, claudin-low (Prat et al., 2010; 
Sorlie et al., 2001). These and more recent analysis have emphasized the importance of 
oncogenic alterations with breast cancer pathogenesis (TCGA, 2012; Banerji et al., 
2012; Sorlie et al., 2001; Stephens et al. 2012). Particularly, each subtype is associated 
with certain gene changes such as TP53 mutation that is commonly found in all 
subtypes (Sorlie et al., 2001). Likewise, luminal subtype is characterized by presence of 
PI3KCA mutations, ErbB2 over-expression in ErbB2 subtype and EGFR over-expression 
is observed in basal like BC. Furthermore, these subtypes also have characteristic gene 
signatures that correspond to that of the cell lineages within the mammary gland i.e. the 
luminal or basal cells (Perou et al., 2000). Cell of origin in which the initiating oncogenic 
transformation occurs plays an important role in determining of breast subtype formation 
(Ince et al., 2007; Keller et al., 2012).  
In this thesis, my major focus was to identify and understand the contributions of 
both the cell type as well as oncogene(s) in determining BC pathogenesis. I utilized 
immortalized stem/progenitor cell lines designated as K5+/K19- and K5+/K19+ cells 
(Zhao et al. 2010) as cellular models to study BC development. These cellular 
precursors were derived from same normal reduction mammoplasty sample and 
therefore provided isogenic cell lines to study development of disease from two different 
cell type from same individual. We over-expressed oncogenes specific to different 
subtype including : mp53, mRas, mPI3K, wtErbB2 or wtEGFR ectopically in K5+/K19- 
and K5+/K19+ cells. Combination of triple oncogene(s)/tumor-suppressor –
mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR were efficient in completely transforming 
these immortalized normal K5+/K19- and K5+/K19+ cells (Bhagirath et al. 2015) as 
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shown by different in-vitro assay as well as led to generation of primary and metastatic 
tumors from the transformed cell lines.  
Xenograft tumors formed by these cells were histologically heterogeneous, with 
variable proportions of luminal, basal-like and claudin-low type components depending 
on the cell types and oncogene combinations. Various tumor associated characteristics 
such as onset or incidence of primary and metastatic tumors were found to be 
determined by both the cell type and oncogenes combination that it expresses. Notably, 
K5+/K19- cells transformed with mRas/mp53/wtEGFR combination had a significantly 
longer latency for primary tumor development than all other cell lines, but were observed 
to have more lung metastasis incidence than same cells (K5+/K19-) expressing 
mRas/mp53/wtErbB2. K5+/K19+ cells with either oncogene combination i.e. 
mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR  overall exhibit shorter primary tumor 
latency, and possess a higher metastatic potential than K5+/K19- cells, suggesting that 
these K19+ progenitors are more susceptible to oncogenesis and metastasis (Bhagirath 
et al. 2015).  
In order to understand the differences in the tumor characteristics for different 
cell type/oncogene combination, I further performed microarray analysis of the primary 
and metastatic tumors from each combination. K5+/K19- derived primary tumors were 
observed to have overall higher expression of EMT markers and transcription factors 
than K5+/K19+ derived tumors. Particularly, K5+/K19- expressing mRas/mp53/wtErbB2 
have even higher expression of EMT markers than same cells expressing 
mRas/mp53/wtEGFR, suggesting a probable effect of oncogene ErbB2 in mediating 
more EMT than EGFR in K5+/K19- cells. We further observed an up-regulated 
expression of patient derived metastasis related gene signatures (Minn et al., 2005) in 
primary from K5+/K19+ expressing mRas/mp53/wtEGFR combination. Likewise, the 
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metastatic tumors from the same combination had a lower EMT gene expression and 
more epithelial like phenotype. These results are in concordance with the known 
literature on markers for metastatic disease and further explained lower metastasis 
latency and higher incidence observed for this combination. Additionally, the results from 
microarray analysis also suggested that expression of EMT markers does not 
necessarily suggest higher metastasis from these primary tumors. Analysis of gene 
expression from metastatic tumors showed up-regulation of amino acid transporter 
SLC6A14. SLC6A14 is involved in amino acid metabolism and its higher expression at 
metastatic sites suggest an important role of this molecule in driving colonization of 
disseminated primary tumors cells. 
We lastly tested the role of oncogene combination mRas/mp53/mPI3K in driving 
tumorigenesis from K5+/K19- and K5+/K19+ cells. As observed previously for 
mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR, oncogene combination 
mRas/mp53/mPI3K also completely transformed K5+/K19- and K5+/K19+ cells and 
allowed tumor formation from either cell types. Importantly, PI3K oncogene shows 
differential effect in mediating EMT phenotype in K5+/K19- and K5+/K19+ cells. 
K5+/K19- cells show complete EMT morphology upon over-expression, while K5+/K19+ 
cells have a mixed epithelial and EMT morphology. PI3K induced EMT morphology led 
to loss of ability to form polarized acini in matrigel and show an up-regulated CD44High, 
CD24Low cell population as compared to K5+/K19+ cells. Tumors from either cell type 
expressing mRas/mp53/mPI3K were also distinct from each other, with K19- forming 
spindle like metaplastic carcinomas, while those from K19+ cells were mixture of 
metaplastic carcinomas and adenocarcinomas. Importantly, when we isolated and 
analyzed tumor cell lines from either combination we observed that these cells possess 
differential CK expression thereby suggesting, that transformation of K19- cells with 
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PI3K oncogene conferred EMT phenotype that is maintained by these cells. Together 
these results suggested that cell types K5+/K19- or K5+/K19+ cells have different 
susceptibility to undergo EMT upon oncogenic transformation. Analysis of gene 
expression inherent in the parental cell lines showed a higher expression of EMT related 
markers in K19- cells as compared to K19+ cells, thereby providing some explanation for 
increased susceptibility of these cells to form EMT like tumors.  
Taken together, we observed that different cell types derived from same 
specimen possess distinct abilities to form primary or metastatic tumors and that 
depends both on the intrinsic nature of these cells as well the oncogene that transformed 
the cells. Given the clinical relevance of K19 expression in breast tumors and CTCs 
(Janni et al.,2016; Kabir et al. 2014) and there increased ability to show metastasis in 
our tumor models, future direction would  be to analyze pathways associated with 
differentially expressed genes present in K19 positive primary or metastatic tumors. 
Besides, understanding the contribution of K19 expression itself and its role in driving 
increased tumor or metastasis would be important to identify gene targets that would 










 Over-expression of oncogene combination mRas/mp53/mPI3K, 
mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR leads to complete in-vitro 
transformation of immortalized stem/progenitor cell lines K5+/K19- and K5+/K19+ 
cells. 
 mRas/mp53/wtErbB2 or mRas/mp53/wtEGFR  transformed K5+/K19- and 
K5+/K19+ cells form heterogeneous tumors in mice that distinct possess luminal-
like, basal-like and claudin-low component. 
 Tumor characteristics such as latency and incidence of primary tumor depend 
both on the nature of cell type as well as the transforming oncogene. 
 Primary tumors derived from transformed K5+/K19- cells overall possess higher 
EMT gene expression than those from K5+/K19+ cells. 
 K5+/K19+ mRas/mp53/wtEGFR combination have up-regulated metastasis gene 
signature explaining the increased susceptibility of these cell/oncogene 
combination in driving early metastasis. 
 K5+/K19- or K5+/K19+ cells show distinct EMT phenotypes upon oncogenic 
transformation by mRas/mp53/mPI3K combination. 
 K5+/K19- cells have increased susceptibility to undergo EMT upon 







































Breast cancer is a heterogeneous disease. Molecular profiling of patient tumors 
has led to identification of different subtypes of breast cancers which exhibit significantly 
different survival outcomes (Prat et al., 2010; Sorlie et al., 2001). Thus, understanding 
the biology and defining the origin of various subtypes of breast cancer is a significant 
area of research. Major part of my thesis has been focused on investigating the 
contribution of cell types and genetic alterations in determining breast tumor 
pathogenesis (described in chapter 2-5). In addition to this, I also examined the role of 
matrix derived mechanical stiffness in regulating breast tumor subtype and progression. 
A major fraction of human mammary gland is composed of the stromal tissue that 
includes ECM proteins, fibroblast and other stromal cells. The ECM provides both 
biochemical as well as mechanical context to the cells of mammary gland (Gjorevski and 
Nelson 2011). It has been long known in literature that density of the mammary gland is 
a strong independent risk factor for development of breast cancer. Correlative studies 
have shown that women with 75% or even denser breast tissue are at an increased risk 
of developing breast cancer than those with less dense tissue (Boyd et al., 2007; Martin 
and Boyd, 2008). High MD is associated with increased deposition of stromal collagen 
and other ECM proteins, thereby suggesting that the microenvironment in these 
mammary glands is altered and it is expected to be mechanically stiffer than those with 
low MD (Alowami et al., 2003; Guo et al., 2001). Furthermore, ECM gene signatures are 
also shown to determine the clinical outcomes for breast cancer patients (Bergamaschi 
et al., 2008). Besides ECM proteins, tumor microenvironment consists of several stromal 
cells that secrete growth factors and other paracrine signals in order to maintain the 
tumorigenicity of cells (Lu et al. 2012). Importance of matrix stiffness in driving pro-
tumorigenic behavior was recently found to be associated with cancer associated 
fibroblasts (CAFs), where activation of mechano-regulated transcriptional factor YAP 
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occurs in response to stiffer matrix, which further promotes a feed forward loop that 
sustains matrix stiffness and subsequent activation of CAFs (Calvo et al. 2013). In 
addition matrix stiffness is also shown to promote in-vitro, malignant phenotypes 
(Chaudhuri et al., 2014; Paszek et al., 2005; Provenzano et al., 2009). Matrix derived 
mechanical forces in dense mammary glands therefore play an important role in driving 
tumor progression.  
Vast literature supports the notion that stem cell behavior is regulated by their 
interaction with the niche that is composed of cells as well as the ECM. ECM is a 
biochemical as well as mechanical modulator of cells; while significant research is 
directed at biochemical cues from niche ECM, little is known about how mechanical 
properties of ECM modulate CSCs, despite a known clinical correlation of increased 
breast stiffness with cancer risk (Bertrand et al., 2013; Boyd et al., 2007). Previous 
studies suggest that matrix stiffness can determine and direct generation of different 
lineages from an uncommitted mesenchymal stem cell (Boyd et al., 2007). It is therefore 
possible that the stiffer microenvironment of the breast tumor tissue can drive 
pathogenesis of a particular subtype. Consistent with this notion, high MD (i.e. stiffer 
breast tissue) is a strong risk factor for development of breast cancer and high stiffness 
correlates with development of aggressive and invasive type of breast tumors in younger 
women (<50 years)(Bertrand et al. 2013) 
Increased matrix stiffness has also been shown to promote invasive and 
proliferative behavior of cells in vitro (Chaudhuri et al., 2014; Paszek et al., 2005; 
Provenzano et al., 2009). Together these findings suggest that matrix generated 
mechanical forces in association with other ECM components may regulate the 
pathogenesis of breast cancer towards more aggressive basal-like subtype. This 
subtype of breast cancer comprise of 15% of all breast tumors and presents significantly 
poor survival of patients in comparison with other subtypes. Given the following 
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association of increased stiffness with disease pathogenesis, we sought to examine the 
role of extracellular mechanical forces to drive breast cancer progression and tumor 
subtype by utilizing artificially generated substrates of varying mechanical stiffness in 
collaboration with Dr. Sangjin Ryu, Assistant Professor, Dept. of Mechanical and 
Materials Engineering, UNL. We observed that high mechanical stiffness from the matrix 










































6.2 MATERIALS AND METHODS 
 
 
Controlled polyacrylamide gel substrates of varying elastic moduli or stiffness 
 
PA gel substrates of different elastic strength were prepared according to the 
published protocols (Lakins et al., 2012; Tse and Engler 2010). Briefly acrylamide and 
bis-acrylamide are allowed to polymerize in different proportions and cross-linked on a 
glass coverslip. Upon polymerization elastic strength of each gel substrate was 
quantified using AFM. Softer gels with elastic moduli <0.4kPa will have stiffness values 
closer to physiologically normal mammary gland while the rigid polyacrylamide gels 
having elastic moduli >4kPa will be considered as stiffer and would represent a tumor 
like condition for the cells (Paszek et al., 2005). In order to allow attachment of cells to 
these gel substrates were functionalized with a very thin layer of ECM proteins present 
as mixture (Matrigel from BD-Bioscience) or individually (Collagen, Fibronectin, Laminin) 
(Lakins et al. 2012). Briefly, glass coverslip with gel substrates were treated with bi-
functional cross-linker Sulpho SANPAH that was linked to acrylamide in a UV crosslinker 
at 594nm wavelength, followed by washing with NaOH and HEPES buffer. These were 
then incubated overnight at 4oC in matrigel solution prepared in NaOH and HEPES 
buffer. After 24hrs coverslips were treated with glycine solution for 1hr at room 
temperature, followed by washing in PBS. These were then equilibrated with α-MEM and 
DMEM (1:1) medium at 37oC till cells were plated on the gels (Lakins et al. 2012).  
 
Cell lines and retroviral/lentiviral infection   
Mutant p53R249S (mp53) in pLENTI-6 (purchased from Addgene) along with 
Invitrogen packaging vector (ViraPowerTM Lentiviral Packaging MIX) were transfected 
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into 293FT packaging cells.  Lentiviral supernatants were collected after overnight 
incubation in fresh DMEM media. TSA54 packaging cells were transfected with retroviral 
constructs, mutant H-Ras Q61L (mRas) in pBABE-hygro or wild type EGFR (wtEGFR) in 
pMSCV-puro vector, together with PIK plasmid for packaging, and viral supernatants 
were collected  (as mentioned above for lentiviral). K5+/K19+ stem/progenitor cell lines 
were infected with viral supernatants to generate cell lines with different gene 
combinations followed by their selection in DFCI-1 medium (Band and Sager, 1989) 
containing hygromycin (15ul/ml) (for mutant H-Ras), blasticidine (15ul/ml) (for mutant 
p53), puromycin (0.5ul/ml) (for wild type EGFR). Breast cancer cell lines MCF-7, T47D, 
MDA-MB231 and MDA-MB468 were cultures in α-MEM growth medium as described 
previously (Zhao et al., 2008). 
 
Antibodies  
The following antibodies were used for western blotting and 
immunofluorescence: specific mouse anti- human α-smooth muscle actin (SMA) (sc-
32251) was from Santa Cruz Biotechnology. Mouse anti-human MUC1 (550486) and rat 
anti-human CD49f (555734) were from BD Bioscience. Mouse monoclonal anti-human 
E-Cadherin (E4.6) antibody. 
 
Immunoflourescence  
Transformed stem or breast cancer cells were cultured for 14 days on gel 
substrates of different stiffness, following which they were fixed with freshly prepared 
10% paraformaldehyde for 10mins. Protocol for immunofluorescence as described 
(Debnath et al., 2003). Briefly formalin fixed cells were washed with 0.1M glycine for 
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30mins, followed by blocking with 10% goat serum for 1 hr. These were then stained 
with rabbit anti-CD49f, and mouse anti-MUC1 antibodies. Goat anti-rat alexa 594 and 
goat anti-mouse alexa 488 conjugated secondary antibodies (Invitrogen) were used for 
staining. The sections were mounted with anti-fade mounting media. Images were taken 

























Growth of different breast cancer cell lines on gel substrates of varying 
mechanical stiffness 
Mechanical stiffness from the ECM has been shown to promote malignant 
phenotypes of epithelial cells (Chaudhuri et al., 2014; Paszek et al., 2005; Provenzano 
et al., 2009). To standardize cancer cells culture on PA gel substrates of varying 
mechanical strength, we assessed growth of different breast cancer cell lines including 
MCF-7, T47D (representative of Luminal subtype), MDA-MB 468 (Basal-like) and MDA-
MB231 (claudin-low) (neve,) on PA gel substrates coated with matrigel and having a 
range of stiffness values from 0.2 or 0.4kPa (Low), 1 or 2.55 kPa (Intermediate), 4.0 
kPa, 10.6 kPa and 40.4 kPa (High) (Tse and Engler 2010). The proliferation of these 
cells varied with the mechanical stiffness of the gel. Lower stiffness condition (0.4 kPa) 
promotes formation of growth arrested acini in MCF-7 and T47D cells and rounded 
morphology for MDA-MB468, MDA-MB231 cells (Figure 6.1). At higher mechanical 
stiffness all the breast cancer cells showed higher proliferation (Figure 6). Besides 
increased proliferation, cells tend to spread more on to the gel surface at higher stiffness 
and show an EMT like morphology (Figure 6.1). These results are in agreement with the 
previous findings where human mammary epithelial cells (hMECs) also showed a similar 

















Figure 6.1: In-vitro culture of different breast cancer cells on PA gel of varying 
stiffness. Representative images of MCF-7, MDA-MB231, MD-MB468 and T47D breast 
cancer cells that were grown on- low (0.2kPa, 0.4kPa), intermediate (1kPa, 2.55kPa) 
and high (4.0kPa, 8.4kPa, 10.6kPa, 34.4kPa or 40.4kPa) mechanical stiffness. Cell 





Matrix derived mechanical stiffness drives EMT like phenotype in cultured breast 
cancer cells 
We further confirmed if the breast cancer lines besides showing phenotypic EMT 
at high mechanical stiffness also undergo changes in the expression of EMT markers. 
Analyses of E-Cadherin expression in MCF-7 cells cultured at different (0.2, 1, 4 and 
40kPa) stiffness by immunofluorescence, showed an overall decrease in expression of 
E-Cadherin at higher mechanical stiffness thereby suggesting a role of stiffness in 
modulating expression of EMT markers (Figure 6.2). We further verified these results by 
assessing protein expression of EMT markers by western blotting.  We observed down-
regulation of E-Cadherin levels at higher stiffness (40kPa) in MCF-7 cells (Figure 6.3A, 
6.3C). Accordingly, an increase in expression of α-SMA was observed in both MCF-7 
and MDA-MB231 cells with increase in mechanical stiffness (Figure 6.3A, 6.3B and 
6.3D). Together these results suggest that increasing mechanical stiffness induces EMT 















Figure 6.2: High mechanical stiffness promotes EMT in breast cancer cells. 
 
         
 
 
Figure 6.2: High mechanical stiffness promotes EMT in breast cancer cells. 
MCF7 cells growing on different stiffness were fixed after 12 days in culture and 
immunostained with anti-E-Cadherin antibody. DAPI (Blue) shows the nucleus. Images 
















Figure 6.3: High mechanical stiffness promotes EMT in breast cancer cells. 
A), B) Western blotting showing expression of EMT markers: E-Cadherin and α-SMA in 
A) MCF-7 cells and B) MDA-MB231 cells cultured at stiffness- 0.2kPa, 1kPa, 4kPa, 
40kPa and glass (cells on coverslip). β-actin was used as loading control for western 
blotting. C), D) Quantitative representation of E-Cadherin and α-SMA expression in 





High mechanical stiffness from matrix promotes self-renewal of transformed 
stem/progenitor cells 
We further tested the effect of varying stiffness in regulating stem/progenitor cell 
line K5+/K19+ transformed by oncogene combination mRas/mp53/wtEGFR. It has been 
recently shown, that human mammary progenitor exhibit increased differentiation in to 
either luminal or myoepithelial lineages when cultured under low or high stiffness 
conditions respectively (Lui et al. 2012). Therefore, we tested the effect of high and low 
matrix stiffness in controlling differentiation from transformed stem/progenitor cells. As 
expected from our previous observation, transformed K5+/K19+ cells exhibit differences 
in cell growth at low and high stiffness, showing formation of growth arrested acini 
structure at low stiffness and an overall higher cell proliferation at high stiffness (Figure 
6.4A).  In addition, when we stained these cells with MUC1 (luminal differentiation 
marker) and CD49f (stem cell marker), we observed that transformed K5+/K19+ cells 
show a higher MUC1 differentiation at lower stiffness (0.48kPa and 2.55kPa) (Figure 
6.4B), whereas the cells at higher stiffness showed a low MUC1 expression, suggesting 
a decreased differentiation of transformed progenitor at high stiffness (10.55kPa and 












Figure 6.4: High mechanical stiffness promotes self-renewal of transformed 
stem/progenitor cells. 
 
       
             
 
 
            
 
Figure 6.4: High mechanical stiffness promotes self-renewal of transformed 
stem/progenitor cells. A) Representative images of mRas/mp53/wtEGFR transformed 
K5+/K19+ cells that were grown on- low (0.48kPa, 2.55kPa), and high (4.0kPa, 8.4kPa, 
10.55kPa or 40.4kPa) mechanical stiffness. Cell images taken at magnification 20X 
show variation in cell growth at different stiffness. B) Immunoflourscence staining of 
transformed stem/progenitor with antibodies anti-MUC1 (green) and anti-CD49f (red) 







Tumor progression is characterized by several changes in ECM and stromal 
compartment of tumor including increased expression of many matrix protein- collagens, 
laminin etc, infiltration of fibroblast and immune cells (Butcher et al., 2009). Together 
these changes facilitate dissemination of tumor cells from the primary site in to the blood 
vessels. Increased matrix stiffness in the primary tumor site promotes breast 
tumorigenesis (Levental et al., 2009; Provenzano et al., 2008). High stiffness has been 
shown to enhance malignant phenotypes from hMECS (Chaudhuri et al., 2014; Paszek 
et al., 2005; Provenzano et al., 2009) and also contributes towards activation of signaling 
pathways that promote proliferation (Provenzano et al., 2009). In accordance to these 
finding we also observed an increased proliferation of breast cancer cell lines and 
transformed stem/progenitor cells at high mechanical stiffness (Figure 6.1, 6.4A). We 
further observed that cells also acquired an EMT like morphology at high stiffness. Upon 
analysis, we observed changes in expression of EMT makers (Figure 6.3) at higher 
stiffness. Our results are concordance with the recent study done by Wei et al.  where 
they also showed a similar effect of high mechanical stiffness in inducing EMT in 
transformed cells. Together these results emphasize a tumor promoting behavior of 
ECM derived stiffness, whereby matrix stiffness contributes to progression of tumor by 
facilitating changes such as EMT that would allow tumors cells to disseminate from their 
primary site.  
Other studies have shown that mechanical stiffness from the substrate can 
control the differentiation of a normal mesenchymal stem cell (Engler et al., 2006). 
These functions of stiffness extend to stem cells derived from tissues of different origin 
such as neural and muscle stem cells (Gilbert et al., 2010; Keung et al. 2011). Matrix 
stiffness can regulate both self-renewal and differentiation of the muscle stem cell 
(Gilbert et al. 2010). It was recently shown that human mammary progenitor exhibit 
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increased differentiation in to either luminal or myoepithelial lineages when cultured 
under low or high stiffness conditions respectively (Lui et al. 2012). Taken together these 
findings strongly support stem cell regulator function of the stiffness. Furthermore 
mechanical stiffness has been also shown to affect retinoic acid induced differentiation in 
neuroblastoma cells. High matrix stiffness in the presence of retinoic acid promotes 
differentiation of neural cancer cells and leads to reduction of oncogenic transcription 
factor N-Myc (Lam et al. 2010). Altogether these studies suggest that ECM stiffness 
have the ability to regulate differentiation under both normal and transformed conditions 
and can therefore also regulate tumor phenotype. We observed a reduction in the 
differentiation ability of transformed stem/progenitor as seen by decreased MUC1 
expression at high mechanical stiffness (Figure 6.4B). Tumor microenvironment 
undergoes changes in the stiffness of matrix as the disease progresses (Butcher et al., 
2009; Lu et al. 2012). Moreover, it has also been observed in patient tumors that 
different subtypes have variable stiffness with aggressive tumors having higher stiffness 
than other subtype (Chang et al. 2013). Basal subtype of BC is characterized by 
presence of stem cell like gene signature, which suggests a stem cell origin of these 
tumors.  
Given these results and our observation, it is likely that higher stiffness regulates 
the CSCs in basal like tumors towards a less differentiated phenotype and together with 
induction of EMT in cells high mechanical stiffness might contribute towards the 
aggressive behavior of these tumors. Further assessment of effect of mechanical forces 
on CSCs in terms of their functional properties in-vivo with respect to tumor subtype 
formation would allow better understanding on etiology of basal like breast tumors and 
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